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SUMMARY  
Replication-competent oncolytic viral therapies have shown great promise preclinically and 
in clinical trials for the treatment of various cancers, with the possible advantages of stronger 
treatment efficacy compared to conventional therapy due to higher tumor selectivity as well 
as lessening side effects. They are able to preferentially and selectively propagate in cancer 
cells, consequently destroying tumor tissue via cell lysis, while leaving noncancerous tissues 
unharmed.  
 
Oncolytic vaccinia virus (VACV) strains have been of particular interest due to several 
advantages. VACV‘s large 192-kb genome enables a large amount of foreign DNA to be 
incorporated without significantly reducing replication efficiency of the virus. It has fast and 
efficient replication, and cytoplasmic replication of the virus lessens the chance of 
recombination or integration of viral DNA into the genome of host cells. Perhaps most 
importantly, its safety profile after its use as a live vaccine in the World Health Organization‘s 
smallpox vaccination program in over 200 million people makes it particularly attractive as an 
oncolytic agent and vector for the delivery of heterologous proteins. 
 
Currently, biopsy is the gold standard for monitoring of viral tumor colonization and 
oncolysis. This may be feasible in preclinical or early clinical trials; however, a noninvasive 
method facilitating ongoing monitoring of viral therapy is needed for human studies. The 
tracking of viral delivery could give clinicians the ability to assess the biodistribution of 
oncolytic viruses to ensure safety and correlation with treatment efficacy. Furthermore, a 
more sensitive and specific diagnostic technique to detect tumor origin and, more 
importantly, presence of metastases may be possible. 
 
This work centers on the construction and testing of a VACV strain, GLV-1h153, carrying the 
human sodium iodide symporter (hNIS) as a marker gene for non-invasive tracking of virus 
by imaging. This virus strain was derived from GLV-1h68, which has already been shown to 
be a simultaneously diagnostic and therapeutic agent in several human tumor models 
including breast tumors, mesothelioma, pancreatic cancers, anaplastic thyroid cancers, 
melanoma, and squamous cell carcinoma. Further, GLV-1h68 is currently undergoing clinical 
trials. Thus, this project aimed to help develop imaging techniques for use in clinical trials of 
oncolytic viral therapy. Further, the feasibility and effectiveness of virally induced targeted 
radiotherapy as an anti-cancer strategy was also investigated. 
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hNIS is an intrinsic plasma membrane protein which mediates the active transport and 
concentration of iodide in the thyroid gland and some extra-thyroidal tissues. It is also one of 
several human genes currently being used as reporters in preclinical studies and has 
already been used in clinical studies for imaging viral replication in prostate cancer. hNIS 
gene transfer via viral vector may allow infected tumor cells to concentrate several carrier-
free radionuclide probes such as Iodide-124 (124I), Iodide-131 (131I), and 99m-Technecium 
Pertechtenate (99mTcO4), which have long been approved for human use. hNIS also has the 
advantage of being of human origin thus minimizing immunogenicity, and its transporter 
based system allows intracellular signal amplification.   
 
GLV-1h153 was tested in pancreatic adenocarcinoma cell line PANC-1. GLV-1h153 
infected, replicated within, and killed PANC-1 cells in cell culture as efficiently as GLV-1h68 
and provided dose-dependent levels of hNIS transgene expression in infected cells. 
Immunofluorescence detected successful transport of the protein to the cell membrane prior 
to cell lysis, which enhanced dose and time-dependent intracellular uptake of 131I. In vivo, 
GLV-1h153 was as safe and effective as GLV-1h68 in regressing pancreatic cancer 
xenografts. In animal models, biodistribution profiles revealed persistence of virus in tumors 
5 weeks post injection, with the virus mainly cleared from all other major organs. Tumor 
infection by virus was confirmed via optical imaging and histology.  
 
GLV-1h153 further facilitated deep tissue imaging of virus replication in tumors via Iodide-124I 
positron emission tomography (PET) as well as 99mTcO4-mediated gamma scintigraphy. This 
was possible with both intratumoral and intravenous injection of the virus with radiouptake 
retained as long as 24 and 48 hours after radiotracer injection. PET image quantitation of 
radiouptake in tumors was found to correlate well with tissue radiouptake counts. Repeated 
radiotracer injection revealed optimal radiotracer uptake around 1-2 weeks post virus 
treatment, with decreasing signals after around 3 weeks. The decrease in signal correlated 
with tumor growth retardation, eventual regression from initial volume at baseline, and 
necrosis on histologic analysis by 5 weeks post treatment. Autoradiography of GLV-1h153-
infected tumors revealed a need for presence of virus (visualized with green fluorescent 
protein expression), viable tissue, and adequate blood flow to enhance radiouptake in 
tumors. Dosimetric analysis of uptake in infected tumors displayed potential for therapeutic 
doses of radiotherapy to be delivered systemically to tumors. When GLV-1h153 was 
combined with 131I for treatment, a modest additive effect was seen as compared to GLV-
1h153 alone.  
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Therefore, Insertion of the hNIS gene does not hinder replication capability of GLV-1h153 
and induced the functional production and transportation of the hNIS protein to the cell 
membrane. GLV-1h153 was also a safe oncolytic agent against pancreatic cancer with a 
promising biosafety profile. GLV-1h153 facilitated time, dose-dependent and hNIS-specific 
intracellular radiouptake both in cell culture and in vivo, facilitating deep tissue imaging via 
PET and gamma scintigraphy with 124I and 99mTcO4, respectively. Radiouptake required a 
combination of viable tissue, blood flow, and presence of virus, and was adequately retained 
at potentially therapeutic levels. GLV-1h153 is thus a promising new candidate for treating 
pancreatic cancer and noninvasively imaging viral therapy. These findings warrant further 
investigation into possible long term monitoring of viral therapy, as well as synergistic or 
additive effects of radioiodine combined with this novel treatment and imaging modality. 
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ZUSAMMENFASSUNG  
 
Therapien mittels replikations-kompetenter onkolytischer Viren zeigten bereits 
vielversprechende Erfolge in klinischen Studien zur Bekämpfung verschiedener 
Krebserkrankungen, wobei der Vorteil der erhöhten Behandlungseffizienz im Vergleich zu 
konventionellen Therapien in der hohen Tumorselektivität und den damit verbundenen 
verringerten Nebenwirkungen zu suchen ist. Die Viren sind in der Lage, sich präferentiell 
und selektiv in Krebszellen zu vermehren, wodurch das Tumorgewebe durch Zelllyse 
zerstört, das gesunde Gewebe jedoch nicht geschädigt wird. 
 
Onkolytische Vaccinia Virus (VACV) Stämme sind aufgrund einiger besonderer 
Eigenschaften von besonderem Interesse. Das 192-kb große Genom der VACV macht es 
möglich, große Stücke fremder DNA in einzufügen, ohne, die Replikationseffizienz der Viren 
wesentlich zu beeinflussen. Die schnelle und effiziente zytoplasmatische Replikation der 
Viren erniedrigt die Chance der Rekombination oder Integration viraler Erbinformation in die 
DNA der Wirtszellen. Möglicherweise am wichtigsten jedoch, ist das bekannte 
Sicherheitsprofil als Lebend-Impfstoff in der von der WHO (World Health Organization) 
initiierten, erfolgreichen Ausrottung der Pocken, welches die VACV als attraktives 
onkolytisches Agens und Vektor für heterologe Proteine erscheinen lässt. 
 
Biopsien sind zurzeit der Gold-Standard zur Überwachung onkolytischer Virus Therapien. In 
der präklinischen und frühen klinischen Phasen ist dies auch durchführbar, doch für weitere 
Studien am Menschen werden Methoden benötigt, die eine nicht-invasive Überwachung der 
Therapie ermöglichen. Das Nachverfolgen der Viren könnte Klinikern die Möglichkeit geben, 
die Verteilung der Viren im Körper nachzuverfolgen, die Effizienz und therapeutische Effekte 
zu korrelieren bzw. die mögliche virale Toxizität zu überwachen. Weiterhin könnten so 
möglicherweise die Sensitivität und Spezifität erhöht werden, wenn es darum geht den 
Ursprung des Tumors, oder noch wichtiger, das Vorhandensein von Metastasen, zu 
detektieren. 
 
Im Fokus dieser Arbeit stand die Konstruktion und das Austesten des VACV Stamms GLV-
1h153, welches das Gen für den humanen Natrium-Iodid-Symporter (hNIS) kodiert, das als 
Reportergen für nicht-invasive bildgebende Nachverfolgung der Viren diente. Der 
Virusstamm leitete sich aus dem bereits beschriebenen Stamm GLV-1h68 ab, welcher 
bereits in einigen Tumor-Modellen (Brust-, Mesothelioma-, Pankreas-, anaplastischen 
Schilddrüsen-, Melanoma- und Plattenepithelkarzinom-Modellen) erfolgreich sowohl als 
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diagnostisches, wie auch therapeutisches Agens eingesetzt wurde, und sich zur Zeit in 
klinischen Studien befindet. Demzufolge diente das hier vorgestellte Projekt der Entwicklung 
von Bildgebungsverfahren, die in der onkolytischen Virustherapie eingesetzt werden können. 
Weiterhin sollte als weitere Strategie zur Krebsbekämpfung die Möglichkeit untersucht 
werden, mit Unterstützung der Viren eine gezielte Radiotherapie durchzuführen. 
 
Bei dem Natrium-Iodid-Symporter handelt es sich um ein intrinsisches Membranprotein 
welches den aktiven Transport und die Anreicherung von Iodid in Schilddrüsenzellen und 
einigen anderen Geweben vermittelt. Zudem wird das Gen, neben einigen anderen 
humanen Genen, bereits in präklinischen Studien als Reportergen verwendet und wurde in 
klinischen Studien bereits zur Darstellung von Viren in Prostata-Krebspatienten benutzt. Der 
Transfer des hNIS-kodierenden Gens mittels viraler Vektoren könnte es ermöglichen, dass 
infizierte Tumorzellen Träger-freie Radionuklidproben wie z.B. Iodid-124 (124I), Iodid-131 
(131I), und 99m-Technecium Pertechtenate (99mTcO4), anreichern, welche schon lange für die 
Verwendung am Menschen zugelassen sind. Weitere Vorteile bei der Verwendung von hNIS 
als Reportergen humanen Ursprungs sind zum einen seine minimale Immunogenität und 
zum anderen die intrazelluläre Signalamplifikation durch die Transportfunktion des Systems. 
 
Der Stamm GLV1h153 wurde in der Pankreas-Adenokarzinom Zelllinie PANC-1 getestet. 
GLV-1h153 konnte diese Zellen infizieren, sich in ihnen replizieren und sie in Zellkultur 
schließlich ebenso effizient abtöten wie GLV-1h68. Zudem wurde eine Dosis-abhängige 
Expression von hNIS in infizierten Zellen nachgewiesen. Immunfluoreszenzanalysen 
bestätigten den erfolgreichen Transport des Proteins an die Zellmembran bevor die Zelllyse 
stattfand, was die Zeit- und Dosis-abhängigen Aufnahme von 131I verstärkte. In vivo war 
GLV-1h153, ebenso wie GLV-1h68, sicher und führte zu einer effektiven Regression der 
Pankreasxenograft Tumoren. Biodistribitionsstudien 5 Wochen nach Injektion, zeigten ein 
Vorhandensein von Viren in Tumoren. In anderen Organen war kein oder kaum Virus 
nachweisbar. Die Infektion des Tumors wurde weiterhin durch optische Bildgebung und 
histologische Untersuchungen bestätigt.  
 
GLV-1h153 ermöglichte weiterhin die Bildgebung von Viren in Tumoren mittels 124I-
abhängiger Positronen-Emissions-Tomographie (PET) sowie 99m-Technecium Pertechnat-
abhängiger (99mTcO4) Gamma Szintigraphie. Die Darstellung konnte sowohl mit 
intratumoral, wie auch mit intravenös applizierten Viren erfolgen, war quantitativ, und die 
Radiotracer konnten bis zu 24 bzw. sogar 48 h nach deren Injektion nachgewiesen werden. 
Die quantitative Analyse der Radionuklidaufnahme aus PET-Bildgebungsdaten korrelierte 
mit den Daten der Bioverteilungsdaten aus isolierten Gewebn. Wiederholte Injektionen des 
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Radiotracers zeigten, dass 1-2 Wochen nach Virus-Injektion die Aufnahme des Tracers in 
den Tumor am höchsten war. Die Signalintensität begann dann 3 Wochen nach Injektion der 
Viren abzufallen, was mit dem Rückgang des Tumors und der letztendlichen Regression und 
der Nekrose in histologischen Untersuchungen 5 Wochen nach Behandlung korrelierte. 
Autoradiographische Untersuchungen von GLV-1h153 infizierten Tumoren zeigten, dass das 
Vorhandensein von Viren (visualisiert durch die viral vermittelte GFP Expression), lebendes 
Gewebe und ausreichender Blutfluss benötigt werden, um die Aufnahme des Radiotracers in 
den Tumor zu erhöhen. Dosimetrische Analysen infizierter Tumoren zeigten das Potential für 
eine systemisch applizierte Radiotherapie des Tumors auf. So führte eine Kombination aus 
GLV-1h153 mit 131I-Behandlung zu geringfügig besseren therapeutischen Erfolgen, als eine 
alleinige Therapie mit GLV-1h153.  
 
Zusammengefasst, hindert die Insertion von hNIS die Replikation von GLV-1h153 nicht und 
resultiert in der Produktion, dem Transport und dem Einbau funktionellen hNIS in die 
Zellmembran. Zudem konnte gezeigt werden, dass GLV-1h153 ein sicheres onkolytisches 
Agens gegen Pankreaskrebs ist, das eine vielversprechende Bioverteilung aufweist. GLV-
1h153 vermittelte Zeit- und Dosis-abhängige sowie hNIS-spezifische intrazelluläre 
Radiotracer-Aufnahme sowohl in Zellkultur wie auch in vivo, was eine Bildgebung tieferer 
Gewebsschichten mittels PET und Gamma Szintigraphie mit 124I bzw. 99mTcO4 ermöglichte. 
Die Aufnahme der Radioaktivität setzte eine Kombination lebenden Gewebes, Blutfluss und 
dem Vorhandensein von Viren voraus und sie konnte in therapeutsich aktvien Dosen 
zurückgehalten werden. GLV-1h153 ist demnach ein vielversprechender Kandidat zur 
Behandlung von Bauchspeicheldrüsenkrebs und zur nichtinvasiven Bildgebung der viralen 
Therapie. Die Ergebnisse untermauern die Notwendigkeit weiterer Untersuchungen und 
Entwicklungen in der Langzeitverfolgung viraler Therapien sowie synergistischer Effekte 
einer Radioiod-Kombinationstherapie mit dieser neuen therapeutischen und bildgebenden 
Substanzklasse. 
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1.0 ONCOLYTIC VIRAL THERAPY 
 
12 million people worldwide will be diagnosed with cancer this year, and 7 million people will 
die from cancer-related causes1. In the United States alone, the figures are estimated at 
1,479,350 new cases and 562,340 deaths in 20092. In Germany, an estimated 340,000 new 
cancer cases are diagnosed annually, and 210,000 lives are lost to cancer related causes, 
making cancer the second leading cause of death in Germany after diseases associated 
with the circulatory system3. Unless dramatic breakthroughs in treatments are achieved, 
cancer will be leading cause of death in Germany within 15 to 20 years. Adding to the 
overwhelming loss of life and decline in quality of life for both patient and family, the 
economic costs associated with a diagnosis of cancer is an immense burden on society 
estimated at $228.1 billion dollars in 2008 in the United States alone2.  
  
Despite advances in conventional therapy, the formidable challenge of treating cancer, 
especially if progressed, still remains. Even with aggressive chemo- and radiation therapy, 
the commonest forms of cancer have not seen improvements in survival rates4. 
Furthermore, despite a prominent increase in cost, anti-cancer drugs approved in 1995 – 
2000 do not show increased efficacy in providing cures from cancer5.  
 
Pancreatic cancer in particular is the fourth leading cause of cancer death in the United 
States6, and objective response to single agent or combination chemotherapies occurs in 
less than 20% of patients which is never curative7. These results explain the active 
investigation underway seeking novel therapeutic strategies for this disease. Developing 
novel therapies, which may also work synergistically in combination with conventional 
treatment options, is vital. 
 
It is well established that combining several treatment modalities appears to be the strongest 
chance of fighting this disease8. Treatments such as surgery, radiation therapy, and 
chemotherapy are often used together to treat multiple different cancer origins. Oncolytic 
viral therapies have also made their mark on the cancer research world as another novel, 
potential therapeutic option, with the possible advantage of lessening side effects as well as 
higher treatment efficacy due to higher tumor selectivity8, 9. In fact, results have been so 
promising that oncolytic viral treatments have now been approved for clinical trials in several 
countries, and the first oncolytic viral therapy has now been marketed as a treatment for 
head and neck cancers in China 10. 
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1.1 What are Oncolytic Viruses? 
 
Oncolytic viruses (OVs) refer to those that are able to preferentially and selectively 
propagate in cancer cells, and consequently destroy tumor tissue leaving non-cancerous 
tissues unharmed11. For a virus to be truly oncolytic, it must possess these qualities. 
Examples of oncolytic viruses studied to date include Newcastle disease virus, adenovirus, 
herpes simplex virus (HSV), vesicular stomatitis virus (VSV), and vaccinia virus, among 
others. The ultimate goal of replication-competent anti-cancerous viral therapy is to produce 
a safe and effective therapeutic index with minimal toxicity and side effects 12. 
 
This chapter presents a summary of the literature available on replication-competent 
oncolytic viruses and will focus on the development of oncolytic vaccinia virus strains. 
 
1.1.1 History of Oncolytic Viruses.  
 
The idea that viruses may be able to treat cancer was born almost by chance, when in the 
early 20th century patients with malignancies who experienced viral infection or received 
rabies vaccinations were noted to experience transient remissions13, 14. Dock, who was the 
first to describe this phenomenon in 1904 when he reported of a patient who underwent 
significant remission of leukemia after experiencing an influenza infection 15. NG De Pace 
described a case of a woman with uterine cancer experiencing remission after a rabies 
vaccination, presenting his findings in 1910 at the International Congress in Paris 16, 17. 
Levaditi et al. then demonstrated that vaccinia virus inhibited various mouse and rat tumors 
in 1922, and described this phenomenon as ―le tumeur fait function d‘eponge‖18.  
 
These early discoveries led to several viruses being tested in both pre-clinical and clinical 
settings during the late 1940s, 50s and 60s8. In the late 1940s, G.T.Pack inoculated live 
attenuated rabies vaccines into human melanoma tumors and reported the first remissions 
at Memorial Sloan-Kettering Cancer Center19-21. Alice Moore laboratory at Memorial Sloan-
Kettering also became a prominent force in the field of oncolytic virotherapy22-24. Working 
with Russian Far East encephalitis virus, complete regression was achieved in some cases 
of mouse sarcoma 180 – the first animal model to demonstrate full regression through viral 
oncolysis22. Hoster et al. published the first clinical trial assessing the impact of viral 
oncolysis on cancer. Twenty-one volunteers with Hodgkin‘s disease were inoculated with 
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samples of tissue and sera from other patients noted to have developed viral hepatitis. 
Development of viral hepatitis in the volunteers was defined at the time of jaundice onset. 
Although there were obviously many significant side effects, some patients did show clinical 
improvement and decreased tumor size after manifesting classic signs and symptoms of 
viral hepatitis 25. In 1956, the National Cancer Institute (NCI) conducted the first large-scale 
clinical study, administering wild-type adenoviruses to 30 patients with cervical cancer and 
achieving varying degrees of localized tumor necrosis but no significant tumor regressions or 
remissions 26.  
 
While these early studies and trials were considered groundbreaking, interest in viruses as 
potential anti-neoplastic therapies was abandoned due to unimpressive and short-lived 
success, as well as unacceptable side-effects that eventually ended trials17. These viruses 
thus failed to infect only malignant cells, failed to replicate only in cancer cells, and were 
unable to circumvent detection and clearance by the immune system. Limited virology, 
molecular biology, immunology, and genetics knowledge, as well as primitive biotechniques, 
likely contributed to this 8. 
 
It is only recently that the fervor of viruses as a strategy against cancer has been reignited 
with the advancement in scientific knowledge and technology. We now possess tools that 
enable us to develop more targeted and effective viruses12. The adenovirus gene deletion 
mutant ONYX-015, which was deleted for the E1B-55K gene and hypothesized to target 
p53-deficient tumor cells, was the first replication-competent modified virus that displayed 
anti-cancer effects in humans27. China is now the first country in the world to market an 
adenoviral therapy for head and neck cancers10. 
 
1.1.2 Why Oncolytic Viruses? 
 
Oncolytic viruses (OVs) have the potential to fulfill many criteria for the ideal cancer 
therapeutic (modified from Breitbach et al.)28:  
1. Cancer therapeutics should be cytotoxic rather than cytostatic;  
2. The new therapeutic must have novel, multi-pronged mechanisms of action in order 
to decrease the onset of resistance;  
3. Novel therapeutics should target or exploit validated genetic pathways and should 
also possess a broad spectrum of efficacy in order to allow for development for 
various markets;  
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4. Beyond having a cytotoxic effect, anticancer agents should ideally cause acute tumor 
debulking, as this facilitates the evaluation of tumor responses, leading to faster, 
lower-cost development. Acute debulking approaches are also complimentary to 
combination therapy with standard (cytostatic) treatments.  
5. The agent‘s route of administration should be flexible, e.g. both IV and IT 
administration should be feasible in order to facilitate systemic tumor targeting as 
well as local boosts of therapeutic to cause tumor debulking;  
6. Novel therapeutics should be a part of a broad product class, with room for 
development of improved next generation products.  
 
With regards to oncolytic viruses: 
1. OVs can directly infect and lyse cancer cells, thereby acting as cytotoxic agents.  
2. OVs can trigger vascular disruption and loss of tumor perfusion shortly following OV 
therapy. An acute inflammatory response was shown to cause vascular shutdown 
and apoptosis of uninfected tumor cells29. In addition, the association of 
immunostimulatory products and antigens from the virus with tumor antigens within 
the tumor microenvironment may ‗tip the balance‘ to rejection of the tumor by the 
host immune response (reviewed in section 2.5 and 2.6).  
3. Advances in genetic engineering have allowed for improved OV targeting and 
potency; many opportunities exist for the development of next generation products. 
Since OVs currently in development exploit validated genetic pathways known to be 
dysregulated in many cancer types (e.g. EGFR/Ras30), OVs may have a broad 
spectrum of efficacy. 
4. Furthermore, evidence of acute tumor debulking in patients was also reported in 
clinical trials. A reduction of tumor perfusion was observed in patients with advanced 
HCC treated with an oncolytic vaccinia virus (JX-594, Jennerex Inc.) within 6 days of 
therapy31.  
5. OVs are replicating therapeutics with unique pharmacokinetics; they are quickly 
cleared from systemic circulation but can rapidly and selectively amplify within tumors 
and may re-emerge systemically (consistent with waves of replication) 31. Therefore, 
OV therapeutics are amenable to both to IV infusion as well as local IT boosts. 
6. Finally, advances in genetic engineering have allowed for improved OV targeting and 
potency; many opportunities exist for the development of next generation products. 
 
 
19 
 
1.1.3 An ‘Ideal’ Replication-Competent Oncolytic Virus.  
 
There are several versions in the literature of what characteristics an ideal replication-
competent oncolytic virus should incorporate. These characteristics may be combined and 
summarized as follows 12, 32, 33:  
 
1. Effective, direct, and preferably complete destruction of tumor cells via lysis;  
2. Preferential or exclusive and rapid infection of tumor cells, ideally also in nondividing 
tumor cells;  
3. Initial evasion of immune system in order to effectively infect and distribute to 
neighbouring cancer cells and cause exponential destruction;  
4. Subsequent autologous anti-tumor response elicited;  
5. Normal tissues are unharmed;  
6. Mild, limited, or no side effects caused, especially in immunocompromized patients;  
7. Treatments are known and available if needed to control or cease replication;  
8. No safety concerns for medical personnel, contacts of the infected individual, or 
public safety;  
9. Stable genetic make-up, especially if virus is modified;  
10. No risk of integration of viral genome into the genome in non-cancerous cells. No 
cells with viral genome contents in host cell genome should survive;  
11. Sufficient genomic carrying capacity;  
12. Unlikely recombination with other organisms; and  
13. Able to be manufactured and distributed for widespread clinical use according to 
‗Good Manufacturing Practices‘ (GMP) guidelines.  
 
An ‗ideal‘ virus has yet to be identified. However, the vaccinia appears to be one of the most 
promising. 
 
1.2 Vaccinia Viruses  
 
In order to develop safer and more efficacious vaccinia viral therapies, it is important to 
understand the history, taxonomy, morphology, and replication of the therapy agent. 
Moreover, an understanding on immune responses of oncolytic viral therapies is also 
needed. 
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1.2.1 History of Vaccinia Viruses as Oncolytic Virotherapies. 
 
Levatidi‘s laboratory were the first to discover vaccinia viruses (VACVs) were naturally 
oncolytic34. Cassel and Garrett followed by successfully treated murine ascites carcinoma35. 
At M.D. Anderson, a patient was witnessed to have remission of Chronic Lymphocytic 
Leukemia after being inadvertently vaccinated with vaccinia virus36, and another patient 
although becoming significantly ill from vaccinia vaccination requiring immunoglobulin had 
remission of his CLL for over 3 years37. Another patient with multiple myeloma had a partial 
response after IV administration of vaccinia virus38. In patients with metastatic renal or 
pulmonary carcinomas also experienced partial remissions38, 39. This lead to several clinical 
trials including treating melanoma with a potent vaccinia virus encoding GM-CSF40, 41, the 
use of thymidine kinase deleted JX-594 encoding the granulocyte macrophage colony 
stimulating factor (GM-CSF) for various cancers42, as well as the parent vaccinia virus 
discussed in this thesis43. Ongoing clinical trials are discussed in section 4.0. 
 
 
1.2.2 Taxonomy. 
 
Vaccinia virus is a member of the Poxviridae family44, 45. Viruses of this family are split into 
two subfamilies, Chordopoxvirinae, which infect vertebrates and Entomopoxvirinae which 
infect solely insects. The subfamily of Chordopoxvirinae is subdivided into eight different 
genera, similar in morphology and host tropism. VACV belongs to the genus Orthopoxviridae 
of the Chordopoxvirinae subfamily, whose members are the causative agents of smallpox. 
Following a massive worldwide effort in the 1970s, the World Health Organisation (WHO) 
declared smallpox to be eradicated in 198046. This effort was due in part to the availability of 
a stable and effective vaccine based on vaccinia virus with sufficient antigenic cross 
reactivity to provide protection to other orthopox viruses. The origins of modern vaccinia 
virus are obscure, and although now known to be distinct from the cowpox virus used in 
1798 by Edward Jenner as a vaccine for smallpox47, it is closely related. Historically the two 
are often considered to be one and the same 46.  
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1.2.3 Morphology. 
 
VACV belongs to the group of double-stranded DNA viruses and is one of the largest known 
viruses. Vaccinia virus particles are approximately 300 x 240 x 120 nm in size and possess 
an oval, brick-shaped structure with a lipoprotein shell surrounding a complex core structure 
45. The core structure contains a linear, dsDNA genome of approximately 192kb, encoding 
for some 200, non-overlapping genes. The double-strand DNA is associated with a number 
of virus-encoded proteins necessary for early transcription of RNA polymerase and enzymes 
for RNA capping, methylation and polyadenylation48. Approximately half of the VV genome is 
transcribed before DNA replication (early class viral genes)49, 50. Minimal interaction with host 
proteins allows VACV to replicate in many different cell types and to avoid host defence 
mechanisms. 
 
At least four distinct types of vaccinia virus particles are produced during productive 
infection: mature virus, also referred to as intracellular mature virus (IMV), intracellular 
enveloped virus (IEV), and two forms of extracellular virus, cell-associated enveloped virus 
(CEV) and extracellular enveloped virus (EEV)45, 51. The IMV particle is surrounded by one 
membrane, and the EEV particle comprises an IMV particle enclosed within a second lipid 
membrane containing several viral antigens52.  
 
1.2.4 Replication. 
 
VACV is unique among most DNA viruses in that its replication occurs in the host cell 
cytoplasm for the duration of the infectious cycle. The first step in infection is the fusion of 
enveloped virus and cell membrane or the membrane of an endocytotic vesicle53. The mode 
of entry is dependent on the particle form. CEVs, EEVs and IMVs use different and yet partly 
unsolved mechanisms and receptors for entry 54. 
 
After fusion of the viral and cellular membranes, the viral core is released into the cytoplasm 
and transported further into the cell along microtubules to the cytoplasmic side of the 
endoplasmatic reticulum (ER). Upon entry into the cytoplasm, the core partially uncoats to 
synthesize early viral mRNAs which resemble host cell mRNAs. The cellular translational 
apparatus is recruited for translation of these mRNAs that encode for proteins involved in 
viral DNA synthesis. Other early proteins serve to modify the host cell (recruitment of the 
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transcriptional and translational apparatus) to the advantage of the virus and aid virus 
escape from the host innate immune response52. After DNA replication has begun in so-
called mini-nuclei, which are surrounded by rough ER membranes, immediate genes and 
late genes are transcribed55. Immediate genes serve mostly for the transcription of late 
genes which are involved in packaging of the new viral particles and for essential proteins 
that initiate early gene transcription in a newly infected cell (Figure 1). 
 
 
Figure 1. Poxvirus replication cycle. Poxviruses replicate in the cytoplasm. Two distinct infectious 
virus particles, the intracellular mature virus (IMV) and the extracellular enveloped virus (EEV), can 
initiate infection. The IMV and EEV virions differ in their surface glycoproteins and in the number of 
wrapping membranes. Fully permissive viral replication is characterized by three waves of viral mRNA 
and protein synthesis (early, intermediate and late), which are followed by morphogenesis of 
infectious particles. The initial intracellular mature virus (IMV) is transported via microtubules and is 
wrapped with Golgi-derived membrane, after which it is referred to as an intracellular enveloped virus 
(IEV). The IEV fuses to the cell surface membrane to form cell-associated enveloped virus (CEV; not 
shown), which is either extruded away from the cell by actin-tail polymerization or is released to form 
free EEV. EEV might also form by direct budding of IMV, therefore bypassing the IEV form. McFaden. 
Poxvirus tropism. 2005. 
23 
 
After synthesis of all the necessary proteins, assembly of progeny virus particles begins56. 
Assembly starts with the formation of crescent-shaped membranes and spherical immature 
virions (IVs) that appear at the sites of DNA replication around 5 hours post infection. These 
IVs still lack the genome and once they take up DNA, they mature into the brick-shaped IMV, 
the first infectious form of the virus57. IMVs will either be released upon cell lysis or 
alternatively move away from DNA sites by binding to microtubules of the host cell, where 
they can obtain a second double membrane from a trans-Golgi or early endosomal 
compartment to form IEVs56. The IEV particles use microtubules and kinesin to propel 
towards and fuse with the cell membrane forming CEVs. CEVs can then recruit actin from 
the cytoplasm to be transported to adjacent cells or dissociate from the cell membrane to 
become EEVs. The latter form has evolved for rapid systemic spread within the host and for 
evasion of immune-mediated clearance. 
 
1.2.5 Host Immune Response to VACV Infection.  
 
In order to develop strategies to combat cancer with oncolytic viruses, it is important to have 
an understanding of the immune response to viruses and virus-colonized tumors. The 
immune system has the capability to hinder or enhance oncolytic viral therapy and anti-
tumor effects, especially in immunocompetent patients. Furthermore, combining 
immunotherapy and oncolytic viral therapy may result in more potent, effective, and 
successful treatment outcomes. By further understanding the pathways and mechanisms of 
the immune response, we may be able to develop more safe, potent, and efficacious 
treatments. 
 
Mammalian host cells are able to initiate immune responses against viruses in order to limit 
viral replication and clear infection 58. They do this through several processes of viral 
recognition and innate defence signaling, inducing immune responses against the viruses. 
Of particular importance are IFNs, especially the type I IFNs, IFN-α and IFN-β. These 
cytokines, and the genes they stimulate, are essential for immune defences against viruses. 
Innate sensing of viruses and induction of IFNs induce three main innate immune responses 
via activation of: 1) the complement cascade; 2) further mediators of inflammation including 
cytokines; and 3) innate immune effector cells such as macrophages and dendritic cells59. If 
pre-existing immunity is present, viruses can also be directly neutralized by circulating 
antibodies60. The innate immune system then orchestrates the lysis of virions and virus-
infected cells, inducing either necrosis or apoptosis, as well as providing a link to adaptive 
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immunity59. Research into the role of innate defences in dampening the oncolytic effects of 
oncolytic viruses has only recently begun, and the importance of this knowledge lies in 
finding avenues to modulate such initial innate responses, in order to allow for efficient viral 
delivery, replication, dissemination, and increased oncolysis of tumors while minimizing host 
toxicity.  
 
Immediately after VACV invasion, antiviral mechanisms involving induction of innate immune 
system complement and productions of interferons (IFNs) and cytokines, are activated and 
serve as the first-line host defence. Recent studies have revealed that vaccinia activates 
innate immunity through a TLR2/MyD88-dependent pathway, resulting in the production of 
pro-inflammatory cytokines and a TLR-independent pathway, leading to the induction of 
antiviral IFN-β production61, 62. Subsequently, adaptive immune responses that are mediated 
by cytotoxic and helper T cells assume importance in defence63. Several studies have 
demonstrated that both the T helper 1 (Th1) and cell-mediated immune responses play a 
critical role in host defence against VACV infection64-67. In addition, neutralizing antibodies 
could also be involved in preventing subsequent VACV infections.  
 
Furthermore, it was demonstrated that antivirus neutralizing antibodies (Abs) were more 
important in clearing VACV than cytotoxic T-lymphocytes (CTLs) following acute infection, 
while in the absence of Abs, CTLs contribute to protection against VACV infection68. 
However, there is still only limited knowledge about the protective immune responses 
against VACV infection. 
 
A number of studies have established the multiple factors encoded by VACV that actively 
suppress innate immunity and the Th1 immune response. Vaccinia virus immunomodulators 
can act either inside or outside infected cells. Intracellular VACV proteins regulate host gene 
transcription (shut off of DNA, RNA, and protein synthesis of cellular origin), the antiviral 
activity of IFNs, innate immune signalling, and apoptosis, whilst extracellular VACV proteins 
inhibit the action of complement, cytokines, and chemokines [for reviews see 48, 69]. Taken 
together, these viral-encoded proteins allow VACV to infect and replicate with remarkable 
efficiency in its host.  
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1.2.6 Host Immune Responses to Tumors Colonized With VACV. 
 
Several studies have been emerging recently specifically looking at the immune response to 
tumors colonized with oncolytic vaccinia viruses. Patients treated with vaccinia expressing 
GM-CSF delivered directly to cutaneous melanoma, for example, demonstrated regression 
of not only the treated lesions but also metastases. The metastases showed no signs of 
vaccinia infection, but did show T cell infiltration70. Therefore, in these experimental settings 
vaccinia was not only able to induce CTL responses against itself, but also against tumor 
cells. Furthermore, studies in immunocompetent mice found that animals cleared of a tumor 
by vaccinia treatment were subsequently resistant to rechallenge by cells of the same tumor 
type, possibly due to the development of immune memory71.  
 
In addition, transcriptional profiling of regressing GI-101A subcutaneous breast xenografts in 
mice treated with the VACV GLV-1h68 based on a mouse-specific platform also revealed 
gene expression signatures consistent with immune defence activation, inclusive of IFN-
stimulated genes (STAT-1 and IRF-7), cytokines, chemokines, and innate immune effector 
function. These findings, the authors concluded, suggested immune activation may combine 
with viral oncolysis to induce tumor eradication in this model, providing a novel perspective 
for the design of oncolytic viral therapies for human cancers43. This was further validated in 
pancreatic and prostate xenograft models, where profiling of immune proteins revealed a 
significant proinflammatory response and marked activation of innate immunity in virus-
colonized tumors72, 73.  
 
Further transcriptional analysis of responding vs. non-responding xenografts infected with 
GLV-1h68 revealed that tumor rejection was associated in vivo with activation of IFN-
stimulated genes and again innate immune host's effector functions correlating with VACV 
colonization of the xenografts. Interestingly, tumors resistant to VACV showed combined 
activation of Th1 and Th2 with a deviation toward Th2 and humoral immune responses that 
failed to achieve rejection, which is possibly explained by a lack of target antigen. Moreover, 
the tumor tolerance model instead displayed immune suppression pathways through 
activation of regulatory mechanisms that included in particular the overexpression of 
interleukin-10 (IL-10), IL-10 receptor, and suppressor of cytokine signaling SOCS-1 and 
SOCS-374. These immune signatures reproduced those observed in humans during 
immune-mediated tissue-specific destruction that causes tumor or allograft rejection, 
autoimmunity or clearance of pathogens75. The authors suggested that there may be 
common pathways in a universal mechanism associated with tumor rejection 76. 
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1.2.7 Why Vaccinia Viruses as Oncolytic Agents. 
 
The advantages of using vaccinia virus as a vector for oncolytic viral therapy are several. 
Vaccinia‘s large genome enables a large amount of foreign DNA to be incorporated without 
reducing the replication efficiency of the virus, which has been shown to be the case with 
some adenoviruses77. It has fast and efficient replication, unlike, for example adenovirus 
ONYX-015. Cytoplasmic replication of the virus lessens the chance of recombination or 
integration viral DNA into cells. Its DNA-based genome also makes it more stable than RNA-
based viruses. It has been shown to be capable of immune evasion, and capable of infecting 
a wide variety of cells. Perhaps most importantly, its safety profile after its use as a live 
vaccine in the WHO‘s smallpox vaccination makes it particularly attractive as an oncolytic 
agent and gene vector46. In addition, a vaccinia immunoglobulin and antiviral drugs are 
available if needed78.  
 
Mechanisms of vaccinia viral oncogenesis remain speculative and unproven. It has been 
shown that oncolytic viruses target cancers that overexpress proteins such as ribonucleotide 
reductase, DNA repair enzymes, and proteins rendering them resistant to apoptosis, 
characteristics that tend to make tumor cells resistant to chemotherapy and radiation 
therapy79. Recently it was discovered that both R1 and R2 subunits of ribonucleotide 
reductase are needed for vaccinia viruses to replicate 80. Although both subunits are already 
encoded in most VACV strains, it suggests that vaccinia viruses may prefer environments 
high in ribonucleotide reductase which may explain vaccinia‘s natural attraction to cancer 
cells. More investigation is needed to elucidate the exact mechanisms rendering vaccinia 
viruses highly selctive and oncogenic in tumors. 
 
 
1.3 Vaccinia Virus in Oncolytic Tumor Therapy 
 
Due to the advantages of vaccinia viruses, several preclinical trials have been performed in 
a variety of cancer origins. Success of these studies has also lead to several clinical trials 
with novel oncolytic viral strains. 
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1.3.1 Preclinical Data. 
 
The successful use of vaccinia virus as an oncolytic agent has been so far published in 
around 50 tumor models (Table 1). This clearly demonstrates the potential of vaccinia virus 
strains to be applicable as tumoricidal agent in a wide variety of cancers. Moreover, as the 
primary tumor is usually not the cause of death, it is important to note that vaccinia virus 
injection has the potential to reduce metastatic burden when, seen with the aggressive PC-3 
prostate cancer model73 or in rabbits bearing VX2 liver tumors81, 82.  
 
Table 1. Vaccinia virotherapy in tumor models. 
Tumor model origin host VV background References 
Prostate 
PC-3 human mouse LIVP 73, 75 
DU-145 human mouse LIVP 73, 75, 83 
Renal 
786-O human mouse WR 84 
ACHN human mouse WR 84 
769P human mouse WR 84 
Renca mouse mouse WR 84 
Pancreatic 
Mia-Paca2 human mouse LIVP 72, 75, 83, 85 
PANC-1 human mouse LIVP 72, 75, 86 
Suit-2 human mouse LIVP 87 
Lung 
A549 human mouse LIVP 75, 83 
TC-1 mouse mouse Not reported 88 
CMT-64 mouse mouse IHD-J 89 
Breast 
GI-101A human mouse LIVP 43, 75 
ZMTH3 dog mouse LIVP 90 
MTH52c dog mouse LIVP 91 
4T1 mouse mouse WR 92 
JC mouse mouse WR(WI) 81, 89 
Brain 
C6 rat mouse WR(vvDD) 93 
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U87MG human mouse WR(vvDD) 93 
U118 human mouse WR(vvDD) 93 
RG2 rat rat WR(vvDD) 93 
F98 rat rat WR(vvDD) 93 
NXS2 mouse mouse VSC20 94 
Squamous cell carcinoma 
MSKQLL2 human mouse LIVP 95 
Mesothelioma 
MSTO-211H human mouse LIVP 96 
Thyroid 
8505C human mouse LIVP 97 
DRO90-1 human mouse LIVP 97 
Multiple myeloma 
My5 human mouse WR 98 
RPMI8226 human mouse WR 98 
Liver 
VX2 rabbit rabbit Wyeth 82 
VX2 rabbit rabbit WR 81, 99 
spontaneous rat rat Wyeth 82 
TIB-75 mouse mouse WR 81 
Colorectal 
MC38 mouse mouse WR 81, 100-103 
LoVo human mouse Copenhagen 104 
HCT116 human mouse WR 101, 105 
CMT-93 mouse mouse WR 92, 105 
HT29 human mouse WR 81 
Ovarian 
OVCAR-3 human mouse LIVP 75 
UCI-101 human mouse WR 92 
SKOV-3 human mouse WR 92 
A2780 human mouse WR 103, 106 
ES2 human mouse LIVP 107 
MOSEC(-luc) mouse mouse WR, LIVP 103, 106, 108 
Defb29 Vegf-
luc 
mouse mouse LIVP 107 
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Melanoma 
1858-MEL human mouse LIVP 75 
888-MEL human mouse LIVP 75 
B16F10 mouse mouse 
Wyeth 
Not reported 
109 
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The use of different oncolytic vaccinia virus strains (WR, LIVP, Wyeth, Copenhagen), 
revealed that WR-derived strains were able to colonize tumors in human xenografts in nude 
as well as syngeneic tumors in immunocompetent wild-type animals, and virus strains 
producing higher amounts of EEV were shown to be better suited to colonize distant 
metastasis and result in faster tumor regression89, 110. LIVP-derived strains, on the other 
hand, are not as well suited to colonize murine tumors but showed a better safety profile in a 
study comparing WR- and LIVP-derived tumor selective strains43. In addition, a LIVP-mutant 
which does produce higher amounts of EEV did not show improved therapeutic potential111. 
Therefore, although different vaccinia virus strains are able to show therapeutic effects in a 
number of tumor models, properties of each strain may be better suited in particular patients 
or tumor origins.  
 
1.3.2 Development of New VACV Generations. 
 
Enhanced understanding and advancements in molecular biology has enabled a generation 
of oncolytic viruses engineered for safer and more efficacious treatments. Several strategies 
have been investigated with regards to vaccinia viruses. 
 
 
1.3.2.1 VACVs Armed With Cytokines / Immunostimulatory Molecules. 
 
One of these strategies relates to the combination of viral therapy with cytokines, which may 
harness the host‘s own immunity to assist tumor rejection and destruction.  
 
As mentioned, thymidine kinase(-) vaccinia virus strains encoding human GM-CSF, JX-549 
and JX-963, were developed81, 82. Both viral strains resulted in enhanced antitumor immunity 
due to the expression of the GM-CSF transgene in situ. Direct oncolysis plus GM-CSF 
expression stimulated shutdown of tumor vasculature and antitumoral immunity, significantly 
reducing tumor burden and increasing median survival. Tumor-specific virus replication and 
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gene expression, systemically detectable levels of GM-CSF, and tumor-infiltrating CTLs as 
well as significant increases in neutrophil, monocyte and basophil concentrations in the 
peripheral blood were also demonstrated.  
 
Expression of T-cell costimulatory molecule 4-1BBL by an oncolytic vaccinia virus resulted in 
modest tumor regression in a poorly immunogenic murine melanoma model109. In a setting 
when lymphodepletion was employed, the expression of 4-1BBL resulted in promoted MHC 
class I expression. At the same time the authors showed reduced antiviral antibody titers, 
enhanced viral persistence, and rescued effector memory CD8+ T cells. This significantly 
improved the therapeutic effectiveness of the oncolytic vector. 
 
Vaccinia expressing co-stimulator cytokines has even been shown to help overcome the 
tumor microenvironment‘s immune suppressive characteristics. The melanoma 
microenvironment in particular has been shown to possibly lead to local T cell tolerance in 
part through downregulation of costimulatory molecules, such as B7.1 (CD80). A 2-dose-
escalation phase I clinical trial was conducted with 12 patients using a recombinant vaccinia 
virus expressing B7.1 (rV-B7.1) for monthly IT vaccination of accessible melanoma lesions. 
The approach was well tolerated with only low-grade fever, myalgias, and fatigue reported, 
with 2 patients experiencing vitiligo112. An objective partial response was observed in 1 
patient and disease stabilization in 2 patients, 1 of who was alive without disease 59 months 
following vaccination. All patients demonstrated an increase in post vaccination antibody and 
T cell responses against vaccinia virus. Local and systemic immunity was evaluated in 
patients demonstrated an increased frequency of gp100 and T cells specific to melanoma 
antigen recognized by T cells 1 (MART-1), and tumor regression was associated with 
increased expression of CD8 and IFN-.  
 
Continuing this work, the effects of a vaccinia virus expressing three costimulatory 
molecules, B7.1, ICAM-1, and LFA-3 (rV-TRICOM) was evaluated in patients with metastatic 
melanoma in a dose escalation phase I trial113. Of the twelve patients followed up, there was 
a 30.7% objective clinical response, with one patient achieving a complete response for 
more than 22 months. An inverse association was detected between anti-vaccinia antibody 
and anti-vaccinia T cell responses, and patients who received high dose IL-2 but failed to 
respond to vaccination had a trend toward improved survival. These studies confirm the 
safety profile and feasibility of direct injection of vaccinia virus expressing multiple 
costimulatory cytokines and molecules in patients with established tumors in order to 
stimulate anti-tumor immunity. 
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Cytokines have even been utilized in order to increase tumor selectivity. Kirn et al. 
developed a vaccinia virus strain expressing the cytokine IFN-β, JX-795, which is incapable 
of responding to this cytokine in order to have the dual benefits as a cancer therapeutic with 
increased anticancer effects and enhanced virus inactivation in normal tissues105. The virus 
was based on a vaccinia B18R deletion mutant backbone for IFN-β expression, as the B18R 
gene product neutralizes secreted type-I IFNs. JX-795 had superior tumor selectivity and 
systemic efficacy when compared with the TK-/B18R- control or wild-type vaccinia in 
preclinical models. The authors concluded that by combining IFN-dependent cancer 
selectivity with IFN-β expression to optimize both anticancer effects and normal tissue 
antiviral effects, tumor-specific replication, IFN-β gene expression, and treatment efficacy 
was achieved following systemic delivery in preclinical models. 
 
1.3.2.2 VACV Delivering Anti-Angiogenic Agents. 
 
Further improvement of the oncolytic potential could recently be achieved in three 
independent studies in which the authors tried to inhibit the tumor vasculature by expression 
of an endostatin/angiostatin fusion gene87 or, as in two of the studies, targeting the 
vasculature endothelial growth factor (VEGF)83, 84. VEGF binds to specific receptors on 
epithelial cells and is a major player in tumor angiogenesis. Inhibition of VEGF has been 
extensively studied in several cancer models84, 114-117, with Avastin being one of the most 
successful immunotherapeutic proteins to date. This drug has been approved by the US 
Food and Drug Administration for use in combination with chemotherapy for treatment of 
metastatic colorectal cancer and most forms of metastatic non-small cell lung cancer118, 119. 
Vaccinia-mediated blocking of VEGF was achieved by either fusing the VEGF receptor 1 to 
the Fc tail of human IgG antibody (VEGFR-1-Ig) or by secretion of a single-chain antibody 
(GLAF-1) to VEGF. In both cases, VEGF was bound and thus prevented interaction to its 
natural receptors on endothelial cells resulting in lower blood vessel densities within the 
tumor tissue. The reduced tumor vascularity was accompanied by faster regression of 
tumors, although in one study, this depended on the dose of virus injected84. In the same 
study the VEGFR-1-Ig encoding vaccinia virus strain was found to be more lethal to mice 
than the parental strain. For the GLAF-1 encoding virus strains no changes in toxicity were 
described. 
 
1.3.2.3 Use of VACVs in Gene Directed Enzyme Prodrug Therapy. 
 
Another approach to enhance the oncolytic effects caused by vaccinia virus strains is the so 
called gene directed enzyme prodrug therapy (GDEPT). Here, a relatively non-toxic prodrug 
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is enzymatically converted to toxic drugs which result in killing of the enzyme producing 
tumor cells. Moreover, the so called bystander effect caused by diffusion of the drug into 
neighboring cells results in killing of cells in close proximity to the enzyme-producing cell 
even if they were not made to express the prodrug converting protein.  
 
The most prominent enzyme type in vaccinia virus-mediated GDEPT certainly is cytosine 
deaminase which is absent in mammalian cells and used in combination with 5-
fluorocytosine104, 106, 120-122. This prodrug is converted to 5-fluorouracil whereby the 
efficiencies depend on the specific cytosine deaminase (e.g. bacterial, fungal) and the 
presence of uracil phosphoribosyltransferase123, 124. When using this system in combination 
with oncolytic vaccinia virus strains, the reported results indicate better therapeutic effects 
when compared to the oncolytic virus alone. However, the therapeutic benefit was expected 
to be higher as recently discussed by Chalikonda et al106. In other studies, similar results 
were found when using a β-galactosidase expressing vaccinia virus strain in combination 
with an inducible prodrug seco-analog of duocarmycin SA125. Several reasons might be 
responsible for these observations: first, the rapid kinetics of oncolytic vaccinia virus 
replication might functionally overlap with the used prodrug system; and second, the 
administration of prodrug may have inhibited the viral replication, thus reducing the 
antitumoral cytotoxicity induced by the oncolytic virus itself. This effect has already been 
reported by McCart et al 126 but was not observed in all prodrug systems 125. Different dosing 
schemes or other GDEPT systems should still be considered and might cause stronger 
synergistic effects between the oncolytic virus strain and prodrug therapy.  
 
1.3.2.4 Combination Therapies with VACVs.  
 
Although the therapeutic effect of vaccinia virus shows promise, combining conventional 
therapies may also be used to enhance oncolytic viral treatment and help circumvent the 
immune system for optimal delivery of viruses to tumors.  
 
Combination of oncolytic vaccinia virus with classical chemotherapeutic agents such as 
gemcitabine and cisplatin led to accelerated tumor size reduction compared to monotherapy 
using VACV alone 72. At the same time each of the chemotherapeutics could only slow down 
tumor growth but did not result in complete tumor regression. Furthermore, 
immunosuppressive chemotherapeutic agents like rapamycin and cyclophosphamide did 
also have beneficial effects in the oncolytic treatment of malignant gliomas in rats93. Injection 
of the immunosuppressive agents resulted in enhanced viral replication and spreading which 
ultimatively led to further prolonged survival of the immunocompetent rats.  
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Combination with other chemotherapeutic agents in future studies will provide useful data as 
to which combination therapies are best suited for each type of cancer.  
 
Radiation therapy has also been explored as a possible strategy against malignancies to be 
used in combination with oncolytic viral therapy127-129. Radiotherapy can either be local in the 
form of external beam radiation therapy (EBRT), or systemically administered. Although 
many oncolytic viral therapies have been combined with radiation therapies including 
adenoviruses, herpes, and vesicular stomatitis viruses (VSV), no studies are present in the 
literautre exploring oncolytic vaccinia viruses in this context. OVs may act as radiosensitizers 
by affecting pathways that render tumors resistant to treatment. Further, the selective 
cytotxicity of viruses to tumors may enable more targeted radiotherapeutic strategies 
especially with systemically administered radiotherapies. This will be discussed in further 
detail in chapter 2. 
 
Further strategies included the use of carrier cells to deliver viruses undetected to tumors. 
An example of such therapy was the development of a cytokine induced killer (CIK) cell that 
expressed non-MHC restricted NKT cell markers and proteins that adhered to abnormal 
vasculature and NKG2D ligands, and which contained vaccinia virus92. The virus was found 
to have a prolonged eclipse period of 48–72 h after infection; and preliminary data indicated 
that virus can be delivered even if faced with an anti-viral immune response. Via whole body 
imaging, the CIK cells was shown to traffick to tumor cells effectively before releasing virus 
throughout the tumor, producing impressive anti-tumor effects. Even previously resistant 
tumors were sensitized to subsequent CIK cell targeting and destruction.  
 
In another innovative strategy complementary oncolytic VSV was combined with oncolytic 
vaccinia virus to improve therapeutic outcome130. The two recombinant viral strains 
synergistically enhanced each other, resulting in a "ping pong" effect which lead to better 
tumor tissue penetration prolonged survival of tumor bearing mice. The synergistic effect 
was on the one hand dependent on the VACV B18R gene product which locally antagonizes 
the innate cellular, antiviral response initiated by type I IFNs131-133 and therefore supports 
VSV growth. On the other hand, recombinant expression of the fusion-associated small-
transmembrane by VSV resulted in enhanced spreading of the VACV.  
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1.4 Vaccinia Viruses in Clinical Trials 
 
Due to the success of vaccinia viruses in preclinical models, there are several ongoing 
clinical phase I and II-studies for human cancer therapy following treatment with oncolytic 
vaccinia virus strains (Table 2). 
 
Table 2. Clinical trials with oncolytic vaccinia viruses. Source: www.clinicaltrials.gov 
Condition Intervention Phase Sponsor 
Advanced Solid 
Organ Cancers 
Biological: Vaccinia virus 
(GL-ONC1) 
Phase 
I 
Genelux 
Corporation 
Solid Cancers 
Biological: Vaccinia virus (vvDD-
CDSR) 
Phase 
I 
University of 
Pittsburgh 
Unspecified Adult 
Solid Tumor 
Biological: recombinant vaccinia-
CEA(6D)-TRICOM vaccine 
Phase 
I 
National Cancer 
Institute (NCI) 
Carcinoma, 
Hepatocellular 
Genetic: JX-594: Recombinant 
vaccinia virus (TK-deletion plus 
GM-CSF) 
Phase 
II 
Jennerex 
Biotherapeutics 
 
For example, seven patients with metastatic melanoma were then recruited for a phase I trial 
utilizing IT injection of JX-59442, 119. Response of both injected tumors (in 5 of 7 patients) and 
response of at least one non-injected tumor (in 4 of 7 patients) was demonstrated, including 
two patients who achieved a partial response (> 6 months) and a complete response (> 4 
months) to JX-594 treatment. Moreover, efficacy and gene expression occurred despite pre-
treatment vaccination and, therefore, pre-existing anti-vaccinia immunity in all patients.  
 
In another phase I trial using JX-594 in patients with hepatic carcinoma, three of ten 
evaluable patients had a partial response and six had stable disease31. Patients received 
one of four doses of IT JX-594 (108 plaque-forming units (PFU), 3x108 PFU, 109 PFU, or 
3x109 PFU) every 3 weeks. The primary goals were to determine the maximum-tolerated 
dose (MTD) and safety of JX-594 treatment. IT injection of JX-594 into primary or metastatic 
liver tumors was generally well-tolerated, with grade I-III flu-like symptoms reported by all 
patients, and four patients experiencing transient grade I-III dose-related thrombocytopenia. 
Grade III hyperbilirubinaemia was dose-limiting in both patients at the highest dose, and thus 
the MTD was calculated at 109 PFU. JX-594 replication-dependent dissemination in blood 
was shown, with resultant infection of non-injected tumor sites. Safety was therefore 
acceptable in the context of JX-594 replication, GM-CSF expression, and systemic 
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dissemination, which led to a phase II trial in patients with unresectable primary 
hepatocellular carcinoma, completed in March 2010119.  
 
Therefore, vaccinia viruses have been shown to be safe and promising in these early clinical 
trials. However, in order to monitor virotherapy, efficacy, and potential toxicity, a non-
invasive imaging modality is needed. This will be discussed in chapter 2. 
  
36 
 
2.0 THE HUMAN SODIUM IODIDE SYMPORTER 
 
As outlined in the previous chapter, oncolytic vaccinia virotherapy has shown success in 
preclinical trials and much promise in completed and ongoing human clinical trials. However, 
as discussed in a review by Breitbach et al.28, a rational clinical development plan is key to 
the development of any novel therapeutic. This involves the following factors: (1) identifying 
an unmet need in medical oncology; (2) identifying a clinically important endpoint that can 
be reached in a reasonable time frame; (3) targeting patient populations that can be enrolled 
efficiently, and finally; (4) identifying a genetic marker to predict tumor response. 
 
Oncolytic viral therapy has addressed most of the key points above. However, regarding 
predicting tumor response, biopsy is the current gold standard for monitoring the therapeutic 
effects of viral oncolysis134. This may be feasible in pre-clinical trials, or early clinical trials, 
however, a non-invasive test facilitating ongoing monitoring of therapy is needed for human 
studies8. This will enable assessment of the biodistribution of oncolytic viruses to ensure 
safety and correlation with treatment efficacy, as well as the potential for a more sensitive 
and specific diagnostic technique to detect tumor origin and, more importantly, presence of 
metastases135.  
 
2.1 Imaging Viral Therapy 
 
Therefore, several noninvasive imaging methods have been developed using ‗reporter 
genes‘, including optical methods using fluorescence and bioluminescence, as well as deep 
tissue imaging modalities utilizing instrumentation such as positron-emission-tomography 
(PET) and single photon emission computer tomography (SPECT) alongside cellular 
transporters. 
 
2.1.1 Optical Imaging. 
 
Optical detection methods such as fluorescence and bioluminescence have the advantage 
of short acquisition times (for fluorescence imaging few milliseconds to several seconds, for 
bioluminescence a few seconds to several minutes) and high spatial resolution. The major 
disadvantage of optical imaging is the inability to perform deep tissue imaging due to 
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autofluorescence, light scattering and the opacity of tissues to light below 600 nm due to 
absorbance by hemoglobin. Nevertheless, optical imaging in small animals has been and 
still is a very important tool to follow the distribution of oncolytic vaccinia viruses equipped 
with genes for luciferases 81, 87, 89, 90, 92, 107, 108, 110, 130 or fluorescent proteins such as green 
fluorescent proteins (GFP)43, 72, 73, 90, 92, 93, 96, 98, 110, 130. Moreover, a GFP-encoding vaccinia 
virus strain (GLV-1h68) currently is in clinical phase I trials in which this fluorescent protein 
can be used to monitor the colonization of near-surface tumors and metastases119, 136. 
The discovery of new fluorescent proteins in the near infrared spectrum will probably result 
in the ability to detect oncolytic viruses in somewhat deeper tissues137. In addition, the 
indirect labelling using fluorescent compounds with emission in the near infrared that bind to 
or are activated by virus encoded proteins may also be developed. 
 
2.1.2 Deep Tissue Imaging. 
 
In contrast to optical imaging, deep tissue imaging modalities such as PET and SPECT (also 
referred to as gamma (γ) scinitgraphy) can be used for non-invasive deep tissue imaging 
utlizing radiotracers with differing properties.  
 
2.1.2.1 Introduction to PET, SPECT, and PET-CT.  
 
Radiotracer imaging technologies are able to measure the distribution of radiotracers in the 
human body138. They are widely available and have a wide range of clinical and research 
applications. Two classes of clinical nuclear imaging systems exist, those designed to image 
single gamma–emitting radionuclides such as 99m-Technecium Pertechtenate (99mTcO4) 
and Iodine-131 (131I), and those designed to image positron-emitting radionuclides such as 
fluorine-18, carbon-11, and Iodine-124 (124I). The single gamma-emitting imaging system is 
referred to as single photon imaging or, when performed tomographically, single photon 
emission computed tomography (SPECT). The positron-emitting imaging system is known 
as positron-emission tomography (PET). PET has greater spatial resolution, higher 
sensitivity and is easier to quantify than SPECT, and is why it was primarily chosen to test 
GLV-1h153‘s ability to facilitate deep tissue imaging. 
 
The potential power of using PET reporter genes in animal research, together with 
technological innovations, has led to the development of dedicated animal PET scanners by 
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a number of research centers in the past 5 years, such as the microPET system139. The 
microPET scanner (Figure 2) has a reconstructed image resolution of 1.8 mm in all three 
axes and has been shown to be fully quantitative140. Further, the volumetric resolution is 
more than an order of magnitude better than state-of-the-art clinical PET systems138. 
 
 
 
 
Figure 2. Focus microPet 120. Dedicated small animal PET scanner, Concorde Microsystems Inc, 
Knoxville, TN. 
 
 
The use of PET reporter genes can play critical roles in developing gene therapies by 
allowing researchers to determine the location, duration, and expression level of transgenes 
and, specifically, 1) develop vector modifications to improve delivery, 2) control expression 
levels, and 3) improve treatments to control duration of expression138. The repeatability, 
quantifiability, and high sensitivity of PET reporter gene systems may lead to rapid 
advancements in our understanding of oncolytic virotherapy. 
 
PET is based on the following principle, reviewed by Chatziioannou AF141. A usually 
cyclotron produced isotope, such as 124I, decays with the emission of a positron. This 
positron travels a small distance in tissue depending on both the tissue density and the 
kinetic energy of the emitted positron. After a series of collisions with atomic electrons from 
the tissues, during which the positron loses its energy and slows down, it annihilates with a 
nearby electron and produces two high-energy photons emitted in opposite directions. The 
simultaneous detection of these photons is the basis of PET imaging. For the most 
commonly used positron emitters, this average distance is on the order of 0.5 mm or less. At 
the point of annihilation, two photons with equal energy of 511 keV are emitted traveling at 
opposite directions conserving the total energy and momentum. These photons travel with 
the speed of light toward the detectors positioned around the subject, where they interact 
and are absorbed, producing an electrical signal. The detector signals are further processed 
by specialized coincidence circuitry and, if the difference in the time of arrival of these 
photons is smaller than a predetermined value (typically ~ 10 ns), the two detectors then 
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define a line of response. Stored events and data are subsequently fed into mathematical 
algorithms, which through a process called ―image reconstruction‖, create the spatial 
distribution of the concentration of the positron emitter in the field of view (FOV). 
Consequently, the concentration of the labeled molecule in tissues can be determined in 
absolute units of mCi/cc.  
 
PET reporter genes encode receptors that bind positron-emitting ligand probes or enzymes 
that modify the positron-emitting substrate probes to produce sequestered positron-emitting 
products138. Cells expressing the PET reporter gene will sequester the radiolabel of the PET 
reporter probe 1) as a ligand bound to the PET reporter receptor or 2) as a ―trapped‖ product 
of the enzymatic reaction of the PET reporter enzyme. Ideally, those cells not expressing the 
PET reporter genes will not retain the PET reporter probe. Since positron-emitting 
radionuclides result in the creation of high-energy gamma rays (511 keV) by positron–
electron annihilation as discussed above, the animal is largely transparent to the wavelength 
of the radiation produced, and visualization of radiolabeled probe/ligand accumulation is 
readily obtained in even deep and visually opaque tissues. Emission computed tomography 
then allows quantitative imaging of the accumulation of the PET reporter probe and, in turn, 
the expression levels of the PET reporter gene. Since PET imaging does not require 
obtaining tissue samples from the subject, this system is noninvasive and can be used to 
repetitively measure reporter gene expression in vivo. 
 
One of the most basic considerations is whether the reporter gene is endogenous or 
exogenous for the organism under scrutiny138. Endogenous genes have the advantage of 
not inducing an immune response thus allowing for repeated studies, however, a high 
background or erroneous signal due to its inherent expression may be a complication. 
Exogenous genes have the disadvantage of possibly inciting an immune response that might 
limit their repeated application. An ideal reporter gene for longitudinal studies should 
therefore produce no immune response and not be normally expressed in the organ under 
consideration. 
 
It is also important to note that radionuclide-based methods offer significant advantages over 
optical-based approaches for imaging reporter gene expression142, 143. Radionuclide-based 
methods offer the highest level of sensitivity for imaging relatively low levels of reporter gene 
expression—as low as 10-12 mol/L of radiolabeled substrate144. This high degree of sensitivity 
may allow the use of relatively weak promoters and the imaging of relatively low levels of 
gene expression  
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2.2 Oncolytic Viruses and Deep Tissue Reporter Genes 
 
Advantages of using replication-selective oncolytic viruses for transgene delivery are 
several145. In addition to their oncolytic capabilities, replicating viruses can deliver 
therapeutic transgenes to image and enhance the probability of tumor eradication through 
multiple avenues. Replication-selective viral systems can employ endogenous viral gene 
expression control signals (promoter/enhancer, polyadenylation, and splice signals) for 
transgene expression. Eliminating the need for exogenous promoters often needed in 
replication deficient systems and polyadenylation signals is an economical use of the often 
limited transgene capacity afforded a replicating viral agent. Using endogenous viral 
promoters may also allow more predictable and controlled transgene expression. Further, in 
contrast to foreign or exogenous promoters, the promoters of the replicating agent are 
optimized for expression in the infected cell.  
 
Viral gene expression during the lytic phase of the viral life cycle of vaccinia virus is highly 
regulated and, as discussed in chapter 1, can be broadly classified into three serially 
activated phases: immediate-early (IE), early (E), and late (L)55. Based on the expression of 
endogenous viral genes, it may be possible to predict the expression kinetics (timing and 
expression levels) of the transgene(s) carried by the replicating agent. Furthermore, when 
multiple transgenes are inserted into a single virus, their expression may be orchestrated to 
occur simultaneously or serially, at levels that will maximize their therapeutic benefit. 
Expressing transgenes serially at different times in the viral lytic cycle is of greatest value 
early in treatment when the infection may be more synchronized. As a viral infection spreads 
and encounters a heterogeneous tumor cell mass, it will likely become asynchronous, 
although the relative expression of different transgenes may still be maintained. 
 
Consequently, novel oncolytic vaccinia virus strains have been generated that express 
proteins, such as thymidine kinase (TK), the human serotonin receptor (hSSTR2) or the 
human norepinephrin transporter hNET, which selectively bind radiotracers and therefore 
should also be detectable in deep tissues of humans86, 120. These viruses will not necessarily 
be used as diagnostic tools, but the possibility to track virus-mediated gene expression will 
help to monitor therapeutic effects, such as control of successful tumor colonization, and 
may help to predict therapeutic effects and potential toxicity. The latter may be significantly 
helpful, as time is needed for oncolytic viruses to regress tumor volume and thus will aid in 
identifying non- or poor-responders for additional therapies.  
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2.2.1 Thymidine Kinase (TK). 
 
Thymidine Kinase (TK) has been used for years in cell culture and animal studies to assess 
cell proliferation. One approach has been use of radiolabeled thymidine or thymidine 
analogues, which are rapidly incorporated into newly synthesized DNA146. Herpes simplex 
virus 1 derived TK (HSV1-TK) has relaxed substrate specificity and so phosphorylates 
thymidine analogues (e.g., 5-iodo-29-fluoro-29deoxy-1-b-D-arabino-furanosyl-uracil [FIAU]) 
as well as acycloguanosine analogues such as acyclovir, ganciclovir (GCV), and penciclovir 
(PCV)147. Cellular enzymes then convert acycloguanosine monophosphates and the 
monophosphate of FIAU to di- and triphosphates, which have been shown to kill cells by 
incorporation as chain-terminating derivatives and/or by inhibition of DNA polymerase148. 
The study by Fong and colleagues was the first to show the successful dose- and time-
dependent monitoring of oncolytic HSV-1 replication in colorectal xenografts149. 
 
However, thymidine analogue tracers are investigational drugs and add a level of regulatory 
complexity that has prevented their clinical usage. Furthermore, the non-human origin of 
HSV1-TK also raises concerns over their potential immunogenicity138. 
 
2.2.2 Human Somatostatin Receptor 2 (hSSRT2). 
 
Other groups have attempted the insertion of the human somatostatin receptor type 2 
(SSTR2) into oncolytic vaccinia viruses for non-invasive imaging. The SSTR2 is targeted by 
the high-affinity synthetic peptide pentetreotide, which is commonly used for receptor 
imaging after being radiolabeled with indium-111150. This receptor is normally expressed in 
human kidney cells and neuroendocrine tumors and gene therapy approaches to deliver the 
SSTR2 to tumors has also been attempted using adenoviral vectors 150, 151.  
 
McCart et al. infected cells with an SSTR2-expressing VACV or controls, and incubated 
them with the somatostatin analog 111In-pentetreotide with or without an excess of 
nonradiolabeled pentetreotide. The SSTR2-infected cells bound 111In-pentetreotide sixfold 
more efficiently than control virus-infected cells and this binding was specifically blocked by 
nonradiolabeled pentetreotide. Further, nude mice bearing subcutaneous murine colon CA 
xenografts were injected intraperitoneally with the SSTR2-expressing VACV or control VACV 
and imaged 6 days later with 111In-pentetreotide-mediated SPECT. Tumors infected with the 
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SSTR2-expressing VACV accumulated higher concentrations of radioactivity compared to 
tumors in animals receiving the control virus. Further, SSTR2-infected tumors were visible 
on imaging 6 days after VACV injection and could be visualized for up to 3 weeks post viral 
injection using repeat radiotracer injections120. 
 
More recently, it was shown that the same VACV encoding the gene for SSTR2 combined 
with the radiotherapeutic 111In-DOTATOC was more effective than either alone at decreasing 
the growth rate of human embryonic kidney HEK-293 cells or colorectal MC-38 cells in 
monolayer152. However, 111In- or 177Lu-DOTATOC combined with parental VACV provided 
equivalent growth inhibition of HEK-293 or MC-38 cells as spheroids, suggesting a 
bystander effect from 111In-DOTATOC. 
 
Nevertheless, radiotracers for SSRT2 require prior radiolabelling for accumulation of 
radioprobes. Further, most radiotracers used with this SSRT2 are able to be imaged with 
SPECT, and it is only recently that newer radioprobes are being developed for higher 
resolution PET imaging153, 154. Furthermore, unlike transporters such as the human 
norepinephrin transporter (hNET) and the human sodium iodide symporter (hNIS), SSTR2 is 
a receptor which usually has a 1:1 binding relationship with radiolabeled ligands and is 
therefore not capable of providing significant amplification through transport-mediated 
concentrative intracellular accumulation of substrate. It is therefore not surprising that 
accumulation of radiotracer was only at around 1.5% ID/gm tissue even 6 days post injection 
of the SSTR2 encoding VACV discussed above120. 
 
2.2.3 Human Norepinephrin Transporter (hNET). 
 
Another deep tissue reporter gene investigated in oncolytic viral strains is the human 
norepinephrin transporter (hNET). hNET is a cell surface human protein belonging to a 
family of Na+/Cl-dependent transporters that contain multiple transmembrane domains, 
mediating the transport of norepinephrine, dopamine, and epinephrine across the cell 
membrane. It can be imaged by SPECT or PET using the radiotracer meta-
iodobenzylguanidine (MIBG)155, 156. The use of the hNET-MIBG reporter imaging is attractive 
since it is of human origin and will unlikely induce an immune response, as well as its limited 
expression in the central and peripheral sympathetic nervous systems157. Moreover, MIBG is 
a standard radiopharmaceutical approved by the U.S. Food and Drug Administration. 
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Previously, attempts to image gene transfer therapy by PET using hNET-MIBG reporter 
imaging were successful in transduced cells and xenografts155. The feasibility of using hNET 
for imaging has also been demonstrated in adenoviral vectors158. 
 
Chen et al. was the first to report on an oncolytic vaccinia virus carrying hNET, GLV-1h9986. 
Like GLV-1h153, this virus is also a derivative of VACV GLV-1h68. The hNET protein was 
expressed at high levels on the membranes of cells infected with GLV-1h99, and expression 
of the hNET protein did not negatively affect virus replication in cell culture or in vivo 
virotherapeutic efficacy. GLV-1h99-mediated expression of the hNET protein in infected cells 
resulted in specific uptake of the radiotracer [131I]-MIBG. In mice, GLV-1h99-infected 
pancreatic tumors were readily imaged by [124I]-MIBG-PET. This virus was further 
investigated by Brader et al. for the imaging of an orthotopic mouse model of human 
malignant mesothelioma using both 123I-MIBG mediated SPECT imaging and 124I-MIBG 
mediated PET imaging159.  
 
A limitation of the hNET symporter is MIBG‘s requirement for radiotracer labeling. The 
question then remained: is there a potential deep tissue imaging reporter gene of human 
origin, which facilitates concentrative intracellular uptake of carrier free radioprobes, able to 
be imaged by high resolution PET imaging? This led to the interest in the human sodium 
iodide symporter (hNIS). 
 
2.3 The Human Sodium iodide Symporter (hNIS) Reporter Gene 
 
Limitations of available reporter genes prompted the testing and discovery of other novel 
reporter genes that may overcome them. This lead to the consideration of the human sodium 
iodide symporter (hNIS), an intrinsic plasma membrane protein which mediates the active 
transport and concentration of iodide in the thyroid gland cells and some extra thyroidal 
tissues, in particular, the lactating mammary gland, as well as in the stomach, salivary 
glands, skin, brain, spleen, small intestine, ovaries, prostate, and testes160.  
 
2.3.1 Biology, Physiology, and Tissue Distribution. 
 
In 1896, Baumann was the first to discover that the thyroid gland concentrates iodide by a 
factor of 20–40 times with respect to plasma under physiological conditions161. Discovery 
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and cloning of the rat NIS by Carrasco and colleagues162 and of the human NIS by Jhiang 
and colleagues163 mediating this uptake opened an exciting and extensive new field of 
research, including exploring the pathophysiological implications of NIS in thyroid disease, 
the therapeutic potential of the gene, and its imaging and diagnostic potential.  
 
hNIS is a glycoprotein with a currently proposed secondary structure of 13 transmembrane 
domains and an estimated molecular mass of around 70–90 KiloDalton (kDa) depending on 
the status of glycosylation (Figure 2)164-167. Glycosylation is not necessary for the function of 
NIS, its stability, or its targeting168. It is located on chromosome 19p13 – 13·2, and is 
composed of 643 amino acids, an extracellular amino-terminus, and an intracellular 
carboxyl-terminus. The coding region has 15 exons interrupted by 14 introns, and codes for 
a 3.9 kb mRNA. The symporter belongs to the sodium/solute symporter family (SSF, TC No. 
2.A.21 (according to the Transporter Classification system)) or solute carrier family 5 
(SCL5A, according to the Online Mendelian Inheritance in Man (OMIM) classification, 
www.ncbi.nlm. nih.gov/Omim/). This family includes more than 60 members of both 
prokaryotic and eukaryotic origin, many of which exhibit a high degree of similarity of 
sequence and function166. 
 
 
Figure 3. Proposed structure of the human sodium iodide symporter. hNIS has 13 
transmembrane domains, an intracellular C terminus, and an extracellular N terminus. All three N-
linked glycosylation consensus sequences are indicated: positions 225 (eL-7), 485 and 497 (eL-13). 
Amino acid residues 389–410 form a transmembrane segment X. Abbreviations: Ct, C terminus; eL, 
extracellular loop; iL, intracellular loop; Nt, N-terminus. De La Vieja et al. Molecular analysis of the 
sodium/iodide symporter: Impact on thyroid and extrathyroid pathophysiology. 2000. 
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Transcriptional activity of thyroidal NIS is primarily regulated by thyroid stimulating hormone 
(TSH), via the cyclic adenosine monophosphate (cAMP) pathway169. Multiple cAMP 
pathways, both protein kinase A (PKA)-dependent and -independent, may be involved in the 
regulation of NIS expression and function. The phosphatidyl-inositol 3-kinase (PI3-K) and 
TGF-β/Smad pathways have been shown to have an inhibitory effect on NIS transcription170, 
171.  
 
Levy et al. 172 studied the biogenesis and post-transcriptional regulation of NIS. They 
showed that NIS is initially synthesized as a precursor protein that is immediately core 
glycosylated in the endoplasmic reticulum168. Further studies have shown that the precursor 
protein is a 56 kDa polypeptide whose maturation into full length 87 kDa polypeptide is first 
observed at about 1 hour and is completed at 3 hours after initial TSH stimulation173. 
Interestingly, NIS protein has an unusually long half-life and remains detectable 10 days 
after TSH deprivation. For active iodide transport to occur, NIS must be expressed, targeted 
and retained in the appropriate plasma membrane surface in polarized epithelial thyroid 
cells174. 
 
 
 
Figure 4. hNIS physiology in the thyroid. hNIS on the basolateral cell membrane of thyroid follicular 
cells cotransporting two sodium ions and one iodide ion into the cell, driven by a sodium gradient 
maintained by sodium-potassium adenosine triphosphatase (ATPase) providing energy for this 
transfer. Once iodide enters cell, it is transported across the apical membrane into the follicular lumen 
by other anion transporters including pendrin. In the follicular lumen, iodide is attached through the 
action of thyroid peroxidase (TPO) to tyrosyl residues along the thyroglobulin (Tg) backbone. Thyroid 
hormones triiodothyronine (T3) and thyroxine (T4) are synthesized by the coupling of two iodotyrosine 
residues and are then stored within the colloid. When thyroid hormone is needed, Tg enters the 
thyroid follicular cell, and thyroid hormone is released into the bloodstream. Modified from Spitzweg et 
al. The sodium iodide symporter: its pathophysiological and therapeutic implications. 2002 
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Once the hNIS is inserted on the basolateral cell membrane of thyroid follicular cells, it 
cotransports two sodium ions and one iodide ion into the cell, driven by a sodium gradient, 
which provides energy for this transfer and is maintained by an oubain sensitive sodium-
potassium adenosine triphosphatase (ATPase) (Figure 4)175, 176. When iodide enters the 
thyroid cell, it is transported across the apical membrane into the follicular lumen by other 
anion transporters including pendrin, which is a chloride-iodide transporter. In the follicular 
lumen, iodide is attached covalently to tyrosyl residues along the thyroglobulin (Tg) 
backbone through the action of thyroid peroxidase (TPO). Thyroid hormones triiodothyronine 
(T3) and thyroxine (T4) are synthesized by the coupling of two iodotyrosine residues and are 
then stored within the colloid. When thyroid hormone is needed, Tg enters the thyroid 
follicular cell, and thyroid hormone is released into the bloodstream. 
 
Although endogenous NIS is physiologically and functionally expressed in several normal 
tissues, so far only 2 cancers have been shown to express endogenous NIS functionally 
making them amenable to radiotherapy, those 2 being thyroid cancers (mainly papillary and 
follicular), and around 80% of human breast cancers including ductal carcinomas177. 
Furthermore, some thyroid tumors such as medullary and anaplastic cancers have been 
shown to lose hNIS expression making them non-amenable to radiotherapy, and some 
papillary cancers have even been shown to de-differentiate, also losing functional hNIS 
expression178.  
 
2.3.2 Imaging Potential. 
 
hNIS gene transfer via viral vector may allow infected tumor cells to concentrate several 
easily attainable, commercially available, and relatively inexpensive, carrier free 
radioisotopes such as 123I, 124I, 125I, 131I, 99mTcO4, rhenium, and astatine for non-invasive 
imaging of NIS expression, all of which have long been approved for human use. In contrast 
to the study published by McCart et al.120, 152 using the VACV-expressing SSTR2, hNIS is a 
transporter-based reporter gene system. Whereas receptors usually have a 1:1 binding 
relationship with a radiolabeled ligand, transporters provide signal amplification through 
transport-mediated concentrative intracellular accumulation of substrate. hNIS use has also 
been shown to be comparable to the commonly used HSV1-tk reporter gene179 and 
correlated with 99mTcO4
180. This can be very useful for viral distribution with scintigraphy or 
PET scanning during and after viral therapy, and may allow for correlation with efficacy and 
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toxicity during clinical trials, thus offering potential clinical translation of this dual therapy. 
Furthermore, the human origin of hNIS likely renders it less immunogenic than other foreign 
reporter genes such as TK. 
 
2.3.3 Therapeutic Potential With hNIS. 
 
In addition, although self-replicating virotherapy has shown great promise for treating cancer, 
the additive or synergistic effects by combining targeted therapeutic systemic radiotherapy 
such as 131I with oncolytic virus-mediated hNIS transfer may eliminate tumors and virus-
resistant tumors. Oncolytic viruses have been found to have a synergistic antitumor effect 
when combined with ionizing radiation181-183. One mechanism for such synergy appears to be 
radiation-induced upregulation of certain cellular DNA repair genes that result in promoting 
viral replication79, 184.   
 
Furthermore, a bystander effect may be possible as 131I undergoes β-particle decay with a 
path length of 0.2–2.4 mm185. It is important to note that 131I is already approved in patients 
for multiple ailments including thyroid cancers and palliation of bone metastasis, and was 
found to be safe with relatively few side effects186. In addition, 131I is not a gene therapy and 
thus involves less risk and complications as compared to gene therapy of cancer. 
 
If additive or synergistic effect is found, patients may be more safely treated with 
combinations of lower doses of virus and radioiodine. Application of carrier-free radioiodine 
would thus be extended, and the extensive experience with radioiodine in thyroid cancer 
management will undoubtedly be helpful in the treatment of other NIS-transfected tumors.  
 
2.3.3.1 Dosimetry and Targeted Radiotherapy. 
 
Radiation dosimetry determines the amount as well as the spatial and temporal distribution 
of energy deposited in matter by ionizing radiation. Internal targeted radionuclide radiation 
dosimetry specifically deals with the deposition of radiation energy in tissue due to a 
radionuclide within the body187. However, unlike external radiation (XRT) dose which can 
often be measured, internal radiation dose must be calculated. By incorporation of 
appropriate radionuclides in appropriately large amounts into target tissue-avid 
radiopharmaceuticals, a sufficiently high radiation dose may be delivered to produce a 
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therapeutic response in tumor or other tissue. With higher administered activities and 
resulting higher normal-tissue doses, however, serious radiation injury can occur.  
 
The main differences between targeted radiotherapy and XRT are caused by dosimetry, with 
dose-rate effects a secondary factor188. In XRT, a target volume is defined, and overlapping 
radiation fields are arranged to treat this volume as evenly as possible. For targeted 
radiotherapy, the absorbed radiation dose is due to the flux of ionizing particles produced by 
radionuclides distributed within or around the tumor. The distribution of radionuclide depends 
on the biologic properties of the tumor. Factors such as the affinity of targeting molecules for 
the tumor cells and the extent and permeability of the tumor vasculature determine the 
intratumoral distribution of targeting molecules. The main theoretic advantage of targeted 
radionuclide therapy is that radiation can be delivered selectively to subclinical tumors and 
metastases that are too small to be imaged and thereby treated by surgical excision or local 
XRT. In addition, the absorbed doses to tumors achieved by targeting may be higher than 
can be delivered by systemic XRT. For any radiation-based therapy, the likelihood of tumor 
cure depends on three factors188: (1) the radiation dose absorbed in the tumor and its pattern 
of delivery; (2) the number of clonogenic tumor cells present. These all have to be destroyed 
to cure the tumor; and (3) the response of the tumor cells to radiation including their 
radiosensitivity, repair capacity and proliferation rate. 
 
Radiopharmaceuticals may be structurally simple, such as ions, to complex, such as 
antibodies, consisting of or labeled with a radionuclide. They may be in solution or in the 
form of a colloid or suspension and may be administered systemically or regionally. 
Historically, radioiodine therapy of thyroid disease including hyperthyroidism and localized 
and metastatic thyroid cancer, has been the most active and successful area of radionuclide 
therapy. Although radioiodine therapy of thyroid disease remains the most widely used form 
of radionuclide therapy, there are a number of newer and/or less frequently applied 
radionuclide therapies including radioimmunotherapy; radiolabeled peptide octreotide or -
octreotate therapy of carcinoid and other tumors over-expressing cell-surface receptors (eg 
somatostatin receptors); and palliative radionuclide therapy of bone pain secondary to 
skeletal metastases using radiopharmaceuticals such as rhenium-186 (186Re)- or rhenium-
188 (188Re)189-191.  
 
The physical characteristics of these radionuclides impose a further level of variability with 
targeted radiotherapy188, 192. The energy spectrum of the ionizing particles determines the 
range of the energy emission, and the distribution of radiation dose throughout a tumor 
depends on tumor size, the radionuclide in use and its intratumoral distribution. This complex 
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situation results in a heterogeneous distribution of radiation dose, which is relatively high in 
some intratumoral regions, and reduced in others. Even in the case of a uniform distribution 
of radionuclide throughout a tumor volume, when the tumor is large in comparison to the 
range of the ionizing particles, most of the energy is absorbed within the tumor. When tumor 
dimensions are smaller than the range, a large proportion of the energy may escape. In 
practice, besides the dosimetric considerations, the selection of a therapeutic radionuclide 
depends on the availability and cost of the radionuclide and the chemical preparation and 
stability, particularly in vivo, of the radiopharmaceutical. 
 
In a seminal paper by O'Donoghue and colleagues, the choice of how radionuclide therapy 
influences the relationship between tumor curability and tumor size was examined188. They 
used a mathematical model to examine tumor curability and its relationship to tumor size for 
twenty-two β-emitting radionuclides that may have therapeutic potential including 131I. The 
model assumed a uniform distribution of radionuclide throughout. They found that for 
targeted radionuclide therapy, the relationship between tumor curability and tumor size is 
different from that for conventional XRT. With targeted radionuclides, there is an optimal 
tumor size for cure. Tumors smaller than the optimal size are less vulnerable to irradiation 
from radionuclides as a substantial proportion of the disintegration energy escapes and is 
deposited outside the tumor volume. The optimal cure size range for 131I was calculated at 
(2.6 - 5.0mm). This may pose an issue for treating micrometastatic disease due to the 
relatively long path length of the β-particle. Further, they conclude that the energy emitted 
per disintegration may also be used to predict optimal cure size for uniform distributions of 
radionuclide. 
 
In systemic therapy, a therapeutic radionuclide is administered either enterally or 
parenterally (typically IVly) and is thus distributed throughout the body via circulatory, 
secretory, metabolic, and/or excretory processes187. In regional therapy, the therapeutic 
radionuclide is introduced directly into a specific space or region of the body and is thus 
mechanically deposited into or on the target region which increases the specificity of dose 
delivery and the therapeutic index is maximized. Although this is the ideal situation for tumor 
therapy, this may miss regions of micrometastasis, and is technically more challenging. This 
thesis concentrates on the systemic therapy of pancreatic tumor xenografts in nude mice.  
 
Serial measurements of activities in normal organs, tumor, and total body can be performed 
by planar gamma camera imaging, SPECT, or positron emission tomography PET193, 194. 
Three-dimensional imaging modalities such as SPECT and PET provide more accurate 
estimates of activities in situ by eliminating the confounding effect of counts from activity in 
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source regions surrounding the structure of interest195, 196. Moreover, with the introduction of 
SPECT-CT197-199 and PET-CT200-202 devices, activity distributions can be accurately 
correlated with anatomy, and tumor and normal-organ masses can be measured in 
conjunction with activity measurements. To determine these activities, regions-of interest 
(ROIs) may be drawn around areas of uptake of organs and/or tumors to determine their 
respective activities, usually expressed as the percentage injected dose per gram tissue 
(%ID/gm). A simplified approach to calculation of tumor and total-body %ID/gm tissue for the 
purposes of this thesis is explained in the methods sections of this thesis. 
 
Although advances have been made in quantitative SPECT203, conventional SPECT remains 
relatively insensitive and slow, requiring a 20- to-40-minute acquisition per bed position. 
Further, propagation of statistical uncertainty in the image reconstruction process degrades 
the precision of SPECT-based activity measurements. PET, on the other hand, offers better 
spatial resolution, higher sensitivity, and generally more accurate and precise activity 
quantitation than SPECT204 and quantitative whole-body PET scans can be completed in 30 
minutes or less. However, as discussed, a limitation of dosimetry calculation is the non-
uniform dose distributions. Scintigraphic imaging modalities such as planar gamma camera 
imaging, SPECT, and even PET), often do not have sufficient spatial resolution to discern 
the heterogeneity of intra-organ and intra-tumor activity distributions205, and normal tissue 
toxicity and tumor therapeutic response may not correlate with average as also 
demonstrated by O‘Donoghue and colleagues192. Thus, in addition to patient-specific 
dosimetry, the issue of spatial non-uniformity of dose at both the macroscopic205-230 and 
microscopic231-251 levels has become an important consideration. 
 
2.4 Preclinical Data 
 
In order to take advantage of the therapeutic and imaging potential of hNIS, several groups 
have attempted exogenous NIS gene transfer in several human cancers in cell culture and in 
rat and mice models. These cancers include head and neck squamous cell cancers, non-
small cell lung, thyroid, liver, colorectal, and prostate cancer, as well as glioma and multiple 
myeloma. Various gene transfer methods have been used, including direct transfer, as well 
as the use of replication-deficient and replication-competent viral vectors. However, these 
experiments have had ranging levels of success. 
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2.4.1 Stable and Vector-Medicated hNIS Transfections. 
 
Several groups have attempted exogenous transfer of hNIS with the aid of electroporation, 
retoroviruses, and replication-deficient adenoviral and baculoviral vectors with varying levels 
of success166, 252, 253. Examples of selective promoters used to drive hNIS expression include 
CEA254, hTERT255, survivin256, and MDR1257. However, several studies report of the rapid 
efflux of iodide from NIS-transfected cells, including anaplastic thyroid and lung cancer cells, 
with no therapeutic effect seen258, 259. To circumvent this problem, Boland et al. constructed a 
recombinant adenovirus encoding the human thyroperoxidase (TPO) gene under the control 
of the cytomegalovirus early promoter (AdTPO). Infection of non-thyroid tumor cells with this 
virus led to production of an enzymatically active protein, and a significant increase in iodide 
organification could be observed in cells co-infected with both AdNIS and AdTPO in the 
presence of exogenous hydrogen peroxide. However, the levels of iodide organification 
obtained were too low to significantly increase the iodide retention time in the target cell260.  
 
On the other hand, other studies have shown that NIS gene delivery into non-thyroidal, non-
organifying tumor cells are capable of inducing accumulation of therapeutically effective 
radioiodine doses, and this was indeed the case in several tumor models. For example, a 
single therapeutic 131I dose of 3 mCi was shown to elicit a dramatic therapeutic response 
using adenovirus-mediated NIS transfer into prostate cell xenografts with an average volume 
reduction of more than 90%261. Further, an Adenoviral vector expressing hNIS regulated by 
MUC1 promoter (Ad-MUC1-NIS) caused a more than 15-fold increase in iodide uptake  in 
infected pancreatic cancer cells in vivo with 123I scintigraphy and an in vivo therapeutic effect 
with 3mci of 131I of >75% reduction in volume of NIS transduced tumors262.  
 
2.4.2 Oncolytic Viruses and hNIS for Imaging and Therapy. 
 
The oncolytic viruses that have been investigated so far in relation to hNIS are 
adenoviruses, measles virus, and vesicular stomatitis virus. To date, however, no one has 
investigated the potential of an oncolytic vaccinia virus vector. A summary of the following 
section is presented in Table 3. 
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2.4.2.1 Adenovirus. 
 
Adenoviruses have shown some success in preclinical trials, however their efficacy in phase 
I trials is often limited by their replication capacity and ability to spread within tumors, and 
there are few examples of complete tumor eradication. 
 
Therefore, several groups have attempted NIS transfer to cells via oncolytic adenoviral 
vectors to improve adenoviral treatment efficacy. Merron et al. were the first to insert the 
hNIS reporter gene in a wild type replicating oncolytic adenovirus (AdlP1) and in an 
adenovirus in which a promoter from the human telomerase gene (RNA component) drives 
E1 expression (AdAM6). The virus induced functional hNIS expression and replication in cell 
culture and kinetics of spread of the different viruses in colorectal tumor xenografts were 
visualized in vivo after IT injection of 109 PFU of virus using 99mTcO4-mediate SPECT. The 
time required to reach maximal spread was 48 h for AdIP1 and 72 h for AdAM6 suggesting 
that hNIS gene insertion in adenoviruses hindered spread in tumors. Maximum radiouptake 
was 4 days post virus injection, suggesting a delay in peak viral replication and hNIS 
expression. However, no significant signal could be reached by day 5 after IT adenovirus 
injection 263. 
 
To further improve adenoviral selectivity, Trujillo et al. constructed of a MUC-1 promoter 
driven, conditionally replicating adenovirus that expresses the NIS (Ad5AMUCH_RSV-NIS) 
for gene therapy of breast cancer264. In cell culture infection of the MUC-1 positive breast cell 
line T47D resulted in virus replication, cytolysis, and release of infective viral particles. 
Conversely, the MUC-1 negative breast cancer cell line MDA-MB-231 did not support viral 
replication. In vivo, mice were maintained on a low-iodine diet and received T4 
supplementation to maximize iodide uptake by tumors while reducing thyroid gland and 
stomach uptake. T47 xenografts were readily imaged using 123I and γ-camera 2 days after IT 
injection of 1 x 1011 of the hNIS-encoding virus with almost 30% uptake 1 hour after 
radiotracer administration. 
 
Hakkarainen et al. created the adenovirus Ad5/3-Δ24-hNIS, a Rb-p16 pathway selective 
infectivity enhanced oncolytic adenovirus encoding hNIS. Ad5/3-Δ24-hNIS replication 
effectively killed prostate cancer cells in cell culture and in vivo265. After 2 consecutive 
injections of 2x108 virus particles ITly, PC-3MM2 tumors retained around 6% of the injected 
dose visualized via 123I-mediated γ-scintigraphy, and interestingly this uptake plateaued until 
around 13 hours post radiotracer administration showing significant retention. Furthermore, 
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Ad5/3-Δ24-hNIS with radioiodide was significantly more effective than virus alone in mice 
with prostate cancer xenografts. 
 
Peerlinck et al. generated the adenovirus AdIP2 encoding hNIS and capable of selective 
replication in colorectal carcinoma cells266. The selectivity of this virus was verified in cell 
culture and in vivo. Its spread in tumors was monitored in vivo using SPECT/CT imaging 
upon 99mTcO4- injection and confirmed by immunohistochemistry. Like AdIP1, replication of 
AdIP2 seemed to be affected by hNIS gene insertion as compared to wild type. Imaging and 
immunohistochemical data showed limited viral spread with maximal hNIS expression 48 
hours after injection of 109 PFU. Administration of a single therapeutic dose of 131I at this 
time point led to a dramatic reduction in tumor size not observed in hNIS-negative viruses.  
 
Next, Merron et al. investigated the potential of hNIS to affect the therapeutic efficacy of 
parental adenovirus dl922-947 following intraperitoneal (IP) administration, in a mouse 
model of peritoneal ovarian carcinoma. In cell culture infection of ovarian carcinoma IGROV-
1 cells with ADAM7 led to functional expression of NIS. However, the insertion of NIS into 
the viral genome resulted in a loss of efficacy of the virus in terms of replication and 
cytotoxicity. In vivo, imaging of IP ovarian xenografts infected with a single IP dose of 1010 
PFU via 99mTcO4-SPECT/CT was only detectable in the peritoneal cavity of animals bearing 
peritoneal ovarian tumors for up to 5 days after IP administration. The study interestingly 
demonstrated that despite the detrimental effect observed in cell culture, insertion of the 
reporter gene NIS in an oncolytic adenovirus did not affect its therapeutic efficacy in vivo267. 
 
Further, Trujillo et al. constructed another conditionally replicating adenovirus in which the 
E1a gene is driven by the prostate-specific promoter, Probasin Ad5PB_RSV-NIS268. In cell 
culture, infection of the prostate cancer cell line LnCaP resulted in virus replication, cytolysis 
and release of infective viral particles. Conversely, the prostate cancer cell line PC-3 
(androgen receptor negative) and the pancreatic cancer cell line PANC-1 did not support 
viral replication. Radioiodine uptake was readily measurable in infected LnCaP cells infected 
with Ad5PB_ RSV-NIS 24 h post-infection, confirming NIS expression. In vivo, LnCaP tumor 
xenografts in nude-mice injected ITly with 1011 PFU of virus expressed NIS actively as 
evidenced by 99mTcO4-SPECT, with signal sustained up to one month after viral therapy. 
Maximum uptake was 12% ID/gm 1 day post virus administration Moreover, administration 
of therapeutic 131I after virus injection significantly increased survival of mice carrying 
xenografted LnCaP tumors compared with virotherapy alone. 
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Promise in these preclinical trials lead to plans for a phase I gene therapy trial in patients 
with prostate cancer utilizing the Ad5-yCD/mutTKSR39rep-hNIS adenovirus 269. To aid in 
these plans, the dosimetric characteristics of the reporter gene system when coupled with IV 
administration of radioactive 99mTcO4 and was determined in a large animal tumor. The virus 
was injected into the prostate gland of dogs for dosimetry purposes, and into a canine soft 
tissue sarcoma for imaging purposes. Using the highest value observed, absorbed radiation 
dose to critical organs was calculated and found to be below U.S. Food and Drug 
Administration limits for diagnostic imaging. Also, 99mTcO4 uptake was readily detected by 
SPECT and found to persist in vivo for at least 4 days. On the basis of dosimetry 
calculations, the authors concluded that up to five imaging procedures can be safely 
performed in humans after intraprostatic injection of the Ad5-yCD/mutTKSR39rep-hNIS 
adenovirus, and the hNIS reporter gene system can be used to study the dynamics of 
adenoviral gene therapy vectors in large animal tumors. 
 
2.4.2.2 Measles virus. 
 
Several groups have also attempted hNIS transfer via oncolytic measles vectors. Dingli et al. 
were the first to show the imaging and therapy potential of hNIS in an oncolytic measles 
vector270. They demonstrated noninvasively by 123I- γ-scintigraphy the IT spread of measles 
virus encoding for hNIS (MV-NIS) in various multiple myeloma xenografts after IT injection of 
2 x106 TCID50. Tumors retained up to 12% to 17% of the injected dose, and showed iodine 
retention up to 24 hours after xenografts. Further, KAS-6/1 xenografts regressed completely 
after a single IV dose of MV-NIS and 131I. 
 
However, due the unfavorable replication kinetics of measles viruses expressing both CEA 
and NIS, Hasegawa et al. tested MV-NIS in combination with another viral construct, MV-
CEA, to treat ovarian cancer SKOV3ip.1 xenografts271. MV-NIS propagation was again 
mapped by serial radioiodine imaging via gamma scanner by systemic injection of 99mTcO4. 
In cell culture studies showed superior replication kinetics of MV-NIS relative to MV-CEA. 
However, γ-scintigraphy was considerably less sensitive than the plasma CEA marker for 
monitoring virus infection. Further, Liu et al. demonstrated that antitumor activity of MV-NIS 
was evident only in measles naive mice-bearing disseminated myeloma, and not in passively 
immunized mice which may limit clinical application of this virus272. 
 
MV-NIS was also shown to be effective with prostate cancer cells for imaging. Infected cells 
concentrated radioiodide isotopes in cell culture by 125I uptake assays. Virus localization and 
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spread in vivo could again be followed by γ-scintigraphy of 123I uptake. After injection of 1.5 x 
106 TCID50 IT or IV, peak tumor uptake was observed on day 4 in IT- and on day 14 in IV-
treated animals with a maximum uptake of around 13% and 14%, respectively. Absorbed 
dose of radiodiodine in the tumor was calculated at an average of 420 or 540 rads/mci when 
MV-NIS was administered IT or IV, respectively, at the time of maximum observed uptake. 
Combination therapy with 131I further enhanced the antitumor effect of MV-NIS virotherapy 
273. 
 
Blechacz et al. investigated MV-NIS’s oncolytic potential and efficiency in tracking viruses in 
animal models of hepatocellular carcinoma. Quantitative analysis of IT iodine uptake via γ-
scintigraphy showed a median IT 123I uptake of 8.41% on day 3 and 9.13% on day 10 in 
Hep3B xenografts with a single IV dose of 2x106 TCID50 of MV-NIS
274. 
 
MV-NIS was further evaluated in pancreatic cancer xenografts275. After injection of 3.5 x 106 
TCID50 of virus directly into BxPC-3 tumors, the maximum average % ID/gm was 
quantitated using 123I-SPECT of tissue and found to be 11.4% on day 2, decreasing 
thereafter at 8.4% on day 3, and 6. 4% on day 5 with wide ranges of uptakes noted. Uptakes 
continued to decrease thereafter. Mice were also maintained on a low-iodine diet and 
received T4 supplementation to maximize iodide uptake by NIS-positive tumors. A significant 
therapeutic effect with virus alone was also seen, and effects of combination therapy in this 
tumor model was then explored276. Dosimetric calculations estimated an absorbed 
intratumoral dose of 1008 rads after IT injection of 3.5 x 106 TCID50. Synergy between MV-
NIS-induced oncolysis and NIS-mediated 131I ablation was not seen; however, a significant 
correlation was observed between NIS-mediated IT iodide localization and peak tumor 
volume reduction with combination MV-NIS and 131I therapy. They concluded that this lack of 
synergy in this model was not due to a lack of radiosensitivity, but rather to a nonuniform IT 
distribution of MV-NIS infection  
 
Due to the large body of promising data with MV-NIS, preparations for clinical trials then 
ensued. Preclinical pharmacology and toxicology studies were conducted in support of the 
clinical protocol for the phase I trial of systemic administration of MV-NIS with or without 
cyclophosphamide in patients with recurrent or refractory multiple myeloma277. On the basis 
of this data, the safe starting dose of MV-NIS for the clinical protocol was set at 106 TCID50 
per patient. Results of this trial are still pending. 
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2.4.2.3 Vesicular Stomatitis Virus (VSV). 
 
In mice with established subcutaneous 5TGM1 myeloma tumors, virus replication and 
spread of a vesicular stomatitis virus, VSV (51)-NIS, was also monitored noninvasively by 
serial gamma camera imaging of 123I biodistribution after IV or IT injection of 5 x 107 
TCID50278. Maximum uptakes were noted at 33.2% and 38.5% ID/gm for the IT and IV 
groups, respectively, 4 days after virus treatment. Dosimetry calculations based on these 
images pointed to the feasibility of combination radiovirotherapy with VSV(51)-NIS plus 131I, 
with a predicted absorbed dose of 1840 and 11.6 rad/mci given IT or IV, respectively, on day 
1 after virus administration. Significant enhancement of tumor regression and survival was 
observed. 
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Table 3. Imaging studies with oncolytic viral vectors encoding hNIS in mouse models. 
 Tumor 
Viral 
dose 
(PFU) / 
route of 
injection 
Radiotracer/ 
imaging 
modality 
Imaging 
time 
points 
Maximum 
uptake 
(%ID/gm) 
/ spread 
Loss 
of 
signal 
T4/low 
iodine 
diet? 
Dosimetry 
(rad/mci) 
Combin
-ation 
Therap
ywith 
131
I? 
Notes 
Refer-
ence 
Adenovirus 
AdlP1 
Colorectal 
HCT-116 
SC  
1 x 10
9
 
single IT 
99m
TCO4/ 
SPECT/CT 
1,2,3,4 dpvi 4 dpvi 5 dpvi No N/A No 
Delay btw max viral 
replication and max 
radiouptake, hNIS 
hindered replication 
263
 
Ad5AMUCH_
RSV-NIS 
Breast 
T47D SC 
1 x 10
11
 
single IT 
123
I / γ-
camera 
2 dpvi 
30% 1 
hpri 
N/A Yes N/A No  
264
 
Ad5/3-Δ24-
hNIS  
Prostate 
PC-3MM2 
SC 
2 x10
8
 IT 
2 x IT   
123
I / γ-
camera 
1 dpvi, 0.5, 
1, 1.5, 2, 4 
/ 13 hpri 
6% 2 hrs 
pri, 
plateaued 
13 hpri 
N/A No N/A Yes 
Uptake plateaued 
up to 13 hrs pri 
265
 
AdIP2 
Colorectal 
HCT-116 
SC 
1 x 10
9
 
single IT 
99m
TCO4 / X-
SPECT/CT 
1,2,3,4,5 
dpvi / 
10mins pri 
N/A 3 dpvi 
Yes 
with 
therapy 
N/A Yes 
Replication 
hindered by hNIS 
insertion 
266
 
ADAM7 
Ovarian 
IGROV-1 
IP 
1 x 10
10
 
single IP 
99m
TCO4 / X-
SPECT/CT 
1-5, 9 dpvi 
~40/mm
3
 
2 dpvi 
5 dpvi No N/A No 
No effect on 
therapeutic efficacy 
267
 
Ad5PB_RSV-
NIS)  
Prostate 
LnCaP    
SC 
1 x 10
11
 
single IT 
99m
TCO4 / X-
SPECT/CT 
1-28 dpvi 
12% 1 
dpvi 
N/A No N/A Yes 
Uptake sustained 
up to 1 month pvi 
268
 
58 
 
Measles Virus 
MV-NIS 
Multiple 
myeloma 
ARH-77, 
KAS-6/1, 
MM1        
SC 
2 x 10
6
 
single IV 
123
I / γ-
camera 
1,3,5,7,15,
24 hpri 
12% - 
17%   1 
hpri 
N/A No 400 
Yes with 
KAS-6/1 
Complete 
eradication of KAS-
6/1 xenografts with 
combination 
therapy 
270
 
MV-NIS 
Ovarian 
SKOV3ip.1          
IP 
1 x 10
6 
 2 
x IP
 
99m
TCO4 / γ-
camera 
1 hpri N/A N/A No N/A No  
271
 
MV-NIS 
Prostate 
LnCaP       
SC 
1.5x 10
6
 
TCID50si
ngle IT/IV 
123
I / γ-
camera 
1,4,5,8,11 
dpvi IT; 
1,4,5,8,11,
14,18 dpvi 
IV 
~ 13% 4 
dpvi IT, 
~14% 14 
dpvi IV 1 
hpri 
N/A No 
420 IT;  
540 IV at 
max uptake 
Yes 
Uptake sustained 
up to 36 dpvi for IV 
273
 
MV-NIS 
Hepatocell
ular      
Hep-3B      
SC 
2 x 10
6 
TCID50 
single IV 
123
I / γ-
camera 
1,3,7,10, 
14 dpvi 
8.41% 3 
dpvi; 
9.13%10 
dpvi;  
N/A No N/A No  
279
 
MV-NIS 
Pancreatic 
BxPC-3    
SC 
3.5x 10
6
 
TCID50si
ngle IT 
123
I / 
SPECT/CT 
2,3,5,8 dpvi 
11.4% 2 
dpvi 
5 dpvi Yes N/A No  
275
 
MV-NIS 
Pancreatic
BxPC-3    
SC 
3.5x 10
6
 
TCID50 
single IT 
123
I / 
SPECT/CT 
2,3,4,6,9 
dpvi 
8% 4 – 6 
dpvi 
9 dpvi Yes 1008 Yes  
276
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Vesicular Stomatitis Virus 
VSV (51)-NIS 
Multiple 
myeloma 
5TGM1  
5 x 10
7
 
TCID502 
x IT/IV  
123
I and 
X-
SPECT 
1,4 dpvi / 
3 hrs pri 
4.1 IT, 7 IV 1 
dpvi; 33.2 IT, 
38.5 IV 4 dpvi  
N/A  No 
1840 IT; 
1160 IV at 
max uptake 
Yes  
278
 
Abbreviations: dpvi = day post virus injection; hprvi = hours post radiotracer injection; IT = intratumoral; IV = intravenous. 
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2.5 Clinical Trials With hNIS 
 
Preclinical imaging and therapy success with NIS gene delivery has lead to several 
completed and ongoing clinical trials (Table 4.). Clinical application of NIS gene delivery 
followed by radioiodine will require the generation and investigation of safe and efficient 
gene delivery systems, as well as the ability for systemic administration and regulated gene 
expression.  
 
Table 4. Clinical trials with oncolytic viruses carrying hNIS. Source: www.clinicaltrials.gov. 
Condition Intervention Phase Sponsor 
Prostate cancer 
Biological: Adenovirus 
(Ad5-yCD/utTKSR39rep-hNIS) 
Phase 
I 
Henry Ford Health 
System, Michigan 
Prostate cancer 
Biological: Adenovirus 
(Ad5CMV-NIS) 
Phase 
I 
Mayo Clinic, 
Rochester 
Multiple Myeloma 
Biological: Measles virus  
(MV-NIS) 
Phase 
I 
Mayo Clinic, 
Rochester 
 
NIS transfer has already been attempted in clinical trials utilizing the replication-competent 
adenovirus Ad5-yCD/utTKSR39rep-hNIS for the imaging of prostate cancer. Men with 
clinically localized prostate cancer were administered an intraprostatic injection of the 
adenovirus. NIS gene expression was imaged noninvasively by uptake of 99mTcO4 in infected 
cells using SPECT. Therapy was shown to be safe with 98% of the adverse events being 
grade 1 or 2. Enhanced radiouptake was detected in the prostate in seven of nine patients at 
1012 PFU but not at 1011, again highlighting the replication inefficiency of this virus. Further, 
expression was monitored and found to increase to around 18% of the total prostate volume 
following injection of 1012 PFU, peaking at 1–2 days post adenovirus injection and detectable 
in the prostate for up to 7 days. No evidence of extraprostatic dissemination of the 
adenovirus was seen by SPECT imaging. The results demonstrate for the first time in 
humans the noninvasive imaging capability of hNIS utilizing an onolytic viral vector269. 
Another trial is also underway investigating the potential of Ad5CMV-NIS for gene therapy 
and combination with radioactive iodine in treating patients with locally recurrent prostate 
cancer that did not initially respond to XRT280. Patients receive intraprostate Ad5CMV-NIS 
followed by dosimetry oral 123I on day 4 and undergo image studies periodically for around 
24 hours for measurement of radioiodine uptake. Patients then receive therapeutic oral 131I 
on day 5. The main aims of this study were to determine the safety and tolerance of 
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Ad5CMV-NIS administered intraprostatically followed by radioiodine treatment in patients 
with locally recurrent adenocarcinoma of the prostate following external beam radiotherapy 
as well as the maximum tolerated dose of Ad5CMV-NIS in these patients.  
Further, a phase I trial has been initiated studying the side effects and best dose of MV-NIS 
when given with or without cyclophosphamide in treating patients with recurrent or refractory 
multiple myeloma280. The time course of viral gene expression and viral elimination, as well 
as the biodistribution of virally infected cells at various time points after treatment with these 
regimens using iodine 123I gamma camera imaging will also be determined. 
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3.0 SPECIFIC AIMS AND HYPOTHESIS 
 
 
This project centers on the construction and testing of a novel oncolytic vaccinia virus 
carrying the human sodium iodide symporter (hNIS) gene on tumor rejection, imaging, and 
targeted radiotherapy in cell culture and mouse models.  
 
 
Hypothesis: The oncolytic vaccinia-hNIS construct, GLV-1h153, will allow killing of tumor by 
direct oncolytic means as well as by additive or synergistically targeted radiotherapy. 
Further, such viral constructs will allow imaging of viral therapy by PET scanning.   
 
 
 
Specific Aim 1: To determine if GLV-1h153 induces the expression of hNIS on the 
cancer cell membranes and assess the effects of gene insertion on viral replication.  
Justification: Since oncolytic viral therapy relies on the replication-competent virus to directly 
kill cancer cells, it is not obvious that a cell surface protein such as hNIS will be expressed 
by a cell infected with virus prior to cell lysis. Based on previous data, parental virus GLV-
1h68 effectively infects, replicates in, and kills many cancer cell types in cell culture. GLV-
1h153 will be compared to parental virus, GLV-1h68, in cell culture in order to determine 
whether insertion of hNIS alters the replication or oncolytic capability of the virus. Further, 
the successful expression and transported of the hNIS to the cell membrane of infected cells 
will be assessed in order to facilitate intracellular radiouptake, as well as the time course and 
dose dependency of hNIS expression and conditions that affect such gene expression. 
 
Specific Aim 2: To establish that GLV-1h153 specifically kills pancreatic cancer cell 
line PANC-1, and is safe when administered in animal models.  
Justification: GLV-1h153 will again be compared to its parental virus, GLV-1h68, in animal 
models in order to determine whether insertion of hNIS alters the cancer - or animal-related 
toxicity. GLV-1h68 is currently in human clinical trials. If GLV-1h153 is found to be effective 
and safe, clinical translation will be possible.   
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Specific Aim 3: To determine if GLV-1h153-induced hNIS expression facilitates 
intracellular uptake of radioiodide, thus enabling imaging of tumor and viral therapy. 
Justification: Successful imaging of hNIS for tracking oncolytic therapy is related to rate of 
infection and internalization of virus, as well as rate of synthesis of hNIS protein and 
localization of protein to the cell surface. Since it is not obvious that a cell surface protein 
such as hNIS will be expressed by a cell infected with virus prior to cell lysis, imaging may 
be negatively affected by rapid cell lysis. This is why the synthetic early (SE) promoter was 
chosen to drive hNIS expression, as protein production under this promoter occurs within 
hours. In this aim, the optimal conditions for imaging will be determined in mouse models. 
The imaging parameters as related route of tracer administration and timing of imaging will 
be investigated. Finding a noninvasive means of tracking viral distribution during and after 
viral therapy allows potential clinical translation for correlation with efficacy and toxicity 
during clinical trials and therapy.   
 
Specific Aim 4: To determine if combination therapy with GLV-1h153 and 131I produces 
additive or synergistic tumor killing.  
Justification: Radioiodine 131I is a standard treatment for cancers that naturally have high 
hNIS expression, such as thyroid cancers. Oncolytic viruses have been found to have a 
synergistic antitumor effect when combined with ionizing radiation. In this specific aim, the 
ability of GLV-1h153-mediated hNIS expression to induce cancers not naturally expressing 
hNIS to concentrate and retain 131I will be investigated. Further, assessment of whether such 
oncolytic viral therapy would be additive or synergistic to treatment by 131I will be examined. 
If additive or synergistic effect is found, patients may be more safely treated with 
combinations of lower doses of virus and radioactive iodine.  
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4.0 MATERIALS AND METHODS  
 
 
4.1 Cell Culture Experiments 
 
4.1.1 Cell Culture. 
 
African green monkey kidney fibroblast CV-1 cells and human pancreatic ductal carcinoma 
PANC-1 cells were purchased from American Type Culture Collection (ATCC) (Manassas, 
VA) and were grown in Dulbecco‘s modified Eagle‘s medium (DMEM) supplemented with 
1% antibiotic-antimycotic solution (Mediatech, Inc., Herndon, VA) and 10% fetal bovine 
serum (FBS) (Mediatech, Inc.) at 37oC under 5% CO2. Rat thyroid PCCL3 cells were a kind 
gift from the lab of Dr. James Fagin at MSKCC and were maintained in Coon‘s modified 
medium (Sigma, St. Louis, MO), 5% calf serum, 2mM glutamine, 1% penicillin/streptomycin, 
10mM NaHCO3, and 6H hormone (1 mU/ml bovine TSH, 10 ug/ml bovine insulin, 10 nM 
hydrocortisone, 5ug/ml transferrin, 10 ng/ml somatostatin, and 2ng/ml L-glycyl-histidyl-lysine) 
at 37oC under 5% CO2.  
 
4.1.2 Construction of hNIS Transfer Vector.  
 
The hNIS cDNA was amplified by polymerase chain reaction (PCR) using human cDNA 
clone TC124097 (SLC5A5) from OriGene as the template with primers hNIS-5 (5′-
GTCGAC(Sal I) CACCATGGAGGCCGTGGAGACCGG-3′) and hNIS-3 (5′-TTAATTAA(Pac 
I) TCAGAGGTTTGTCTCCTGCTGGTCTCGA-3′). The PCR product was gel purified, and 
cloned into the pCR-Blunt II-TOPO vector using Zero Blunt TOPO PCR Cloning Kit (Incell 
culturegen, DeSchelp, Netherlands). The resulting construct pCRII-hNIS-2 was confirmed by 
sequencing to be identical to the source template TC124097. The hNIS binding test 
suggested that the sequence amplified from the cDNA clone TC124097 was not functional. 
A further sequence analysis indicated that the hNIS in the TC124097 contained a 33-bp 
extra sequence in the middle of the coding region when compared to the SLC5A5 sequence 
in GenBank (accession number NM_000453). The following procedure was employed to 
remove this 33-bp segment. The hNIS template in the pCRII-hNIS-2 was amplified 
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separately with the primer pair hNIS-5 and hNIS-a3 (5′-
GAGGCATGTACTGGTCTGGGGCAGAGATGC-3′), and the primer pair hNIS-a5 (5′-
CCCAGACCAGTACATGCCTCTGCTGGTGCTG-3′) and hNIS-3. The PCR products were 
purified from the gel, and mixed as the template for the second PCR with the primers hNIS-5 
and hNIS-3. The second PCR product was then gel purified, and cloned into the pCR-Blunt 
II-TOPO vector. The insert was confirmed by sequencing to be identical to the SLC5A5 
sequence presented in the NM_000453, and designated as hNISa (the 33-bp segment was 
removed). The hNIS cDNA was then released from pCRII-hNIS-2 with Sal I and Pac I, and 
subcloned into HA-SE-RLN-7, HA-SL-RLN-3, and HA-SEL-RLN-2 with the same cuts by 
replacing RLN cDNA. The resulting construct HA-SE-hNIS-1 were confirmed by sequencing 
and used for insertion of PE-hNIS, PL-hNIS, and PEL-hNIS into the HA locus of GLV-1h68.   
 
4.1.3 Generation of hNIS-Expressing VACV.  
 
CV-1 cells were infected with GLV-1h68 at a multiplicity of infection (MOI) of 0.1 for 1 hour, 
then transfected using Fugene (Roche, Indianapolis, IN) with the hNIS transfer vectors. 
GLV-1h68 was derived from VACV LIVP, as described previously43. Two days postinfection, 
infected/transfected cells were harvested and the recombinant viruses selected and plaque 
purified. The genotype of hNIS-expressing VACV GLV-1h153 was verified by PCR and 
sequencing. Also, expression of GFP and β-galactosidase was confirmed by fluorescence 
microscopy and 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal, Stratagene, La 
Jolla, CA), respectively, and lack of expression of gusA was confirmed by 5-bromo-4-chloro-
3-indolyl-β-D-glucuronic acid (X-GlcA, Research Product International Corp., Mt. Prospect, 
IL). 
 
4.1.4 Viral Growth Curves. 
 
PANC-1 cells were seeded onto 24-well plates at 5 × 105 cells per well. After 24 hours in 
culture, cells were infected with either GLV-1h153 or GLV-1h68 at an MOI of 0.01 or 1.0. 
Cells were incubated at 37º C for 1 hour with brief agitation every 30 minutes to allow 
infection to occur. The infection medium was then removed, and cells were incubated in 
fresh growth medium until cell harvest at 1, 24, 48, and 72 hours postinfection. Viral particles 
from infected cells were released by 3 freeze-thaw cycles, and titers determined as medium 
(PFU/mL) in duplicate by plaque assay in CV-1 cell monolayers.  
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4.1.5 Flow Cytometry. 
 
Cells were seeded on 6-well plates at 5 × 105 cells per well. Wells were then infected at 
MOIs of 0, 0.01, and 1.0, and cells then harvested at 6, 12, 24, 48, 72, and 96 hours post 
infection by trypsinizing and washing with phosphate-buffered saline (PBS). GFP expression 
was analyzed via a Becton-Dickinson FACScan Plus cytometer (Becton-Dickinson, San 
Jose, CA). Analysis was performed using CellQuest software (Becton-Dickinson). Cells were 
seeded on 6-well plates at 5 × 105 cells per well. Wells were then infected at MOIs of 0, 0.01, 
0.1, 0.5, 1.0, 2.0, and 5, and were harvested at 24 hours after infection. Cells were 
subsequently trypsinized, washed with phosphate-buffered saline (PBS), and assayed for 
GFP expression on a Becton-Dickinson FACScan Plus cytometer (Becton-Dickinson, San 
Jose, CA). Analysis was performed using CellQuest software (Becton-Dickinson). 
 
4.1.6 Cytotoxicity Assay. 
 
PANC-1 pancreatic cancer cells were plated at 2 × 104 per well in 6-well plates. After 
incubation for 6 hours, cells were infected with GLV-1h153 or GLV-1h68 at MOIs of 1.0, 
0.10, 0.01, and 0 (control wells). Viral cytotoxicity was measured on day 1 and every second 
day thereafter by lactate dehydrogenase (LDH) release assay. Results are expressed as the 
percentage of surviving cells as compared to uninfected control.   
 
4.1.7 hNIS mRNA Analysis Via Microarray. 
 
To evaluate the level of hNIS mRNA production in infected cells, cells were plated at 5 × 105 
cells per well and infected with GLV-1h153 at an MOI of 5.0. Six and 24 hours postinfection, 
3 samples of each MOI were harvested and lysis performed directly using RNeasy mini kit 
protocol (Qiagen Inc., Valencia, CA). The mRNA samples were measured by 
spectrophotometer for proof of purity and hybridized to HG-U133A cDNA microarray chips 
(Affymetrix Inc, Santa Clara, CA) by the genomic core laboratory at Memorial Sloan-
Kettering Cancer Center (MSKCC). The chip images were scanned and processed to CEL 
files using the standard GCOS analysis suite (Affymetrix Inc). The CEL files were then 
normalized and processed to signal intensities using the gcRMA algorithm from the 
Bioconductor library for the R statistical programming system. All subsequent analysis was 
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done on the log (base 2) transformed data. To find differentially expressed genes a 
moderated t-test was used as implemented in the Bioconductor LIMMA package. To control 
for multiple testing the False Discovery Rate (FDR) method was used with a cutoff of 0.05.  
 
4.1.. hNIS Protein Analysis Via Western Blot. 
 
To confirm whether the hNIS protein was being expressed in infected cells, cells were plated 
at 5 × 105 per well and infected with GLV-1h153 at various MOIs of virus, harvested at 24 
hours, and suspended with SDS-page and 0.5-m DDT reagent. After sonication, protein 
samples were loaded on 10% Bis-Tris-HCl buffered polyacrylamide gels using the Bio-rad 
system (Bio-rad laboratories, San Francisco, CA). Following gel electrophoresis for 1 hour, 
proteins were transferred to nitrocellulose membranes using electroblotting. Membranes 
were then preincubated for 1 hour in 5% low fat dried milk in TBS-T (20 mm Tris, 137 mm 
NaCl, and 0.1% Tween-20) to block nonspecific binding sites. Membranes were incubated 
with a purified mouse antibody against hNIS at 1:100 dilution (Abcam Inc., Cambridge, MA) 
and incubated for 12 hour at +4°C. After washing with TBS-T, secondary antibody 
(horseradish peroxidase-conjugated goat antimouse IgG (Santa Cruz, San Diego) was 
applied for 1hour at room temperature at a 1:5,000 dilution. Peroxidase-bound protein bands 
were visualized using enhanced chemiluminescence Western blotting detection reagents 
(Amersham, Arlington Heights, IL) at room temperature for approximately 1 minute and 
using Kodak BIOMAX MR film for exposure. Normal human thyroid lysate was used as a 
positive control, and cells treated with an MOI 1.0 of GLV-1h68 and PBS were used as 
negative controls. 
 
4.1.9 Immunofluorescence. 
 
PANC-1 cells grown in a 12-well plate at 1 × 106 were mock-infected with GLV-1h68 or 
infected with GLV-1h153 at an MOI of 1.0. Twenty-four hours after infection the cells were 
fixed with 3.7% paraformaldehyde, permeabilized with methanol, blocked with PBS 
containing BSA, and incubated with a mouse anti-hNIS monoclonal antibody (Abcam Inc., 
Cambridge, MA) at a dilution of 1:100, followed by incubation with a secondary red 
fluorochrome-conjugated goat antimouse antibody (Incell culturegen) at a dilution of 1:100. 
Pictures were taken using a Nikon inverted fluorescence microscope. 
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4.1.10 Cell Culture Radiouptake Assay. 
 
Radiouptake in cells infected with GLV-1h153 was compared to rat thyroid cell line 
endogenously expressing NIS (PCCL3) and to cells infected with an MOI of 1.0 of parental 
virus GLV-1h68. Cells were plated at 5 × 105 cells per well in 6-well plates. Twenty-four 
hours after infection, cells were treated with 500 uCi of either carrier free 131I or 131I with 1 
mM of sodium perchlorate (NaClO4), a competitive inhibitor of hNIS for a 60-minute 
incubation period. Media was supplemented with 10 uM of sodium iodide. Iodide uptake was 
terminated by removing the medium and washing cells twice with PBS. Finally, cells were 
solubilized in lysis buffer for residual radioactivity, and the cell pellet-to-medium activity ratio 
(cpm/g of pellet vs. cpm/mL of medium) calculated from the radioactivity measurements 
assayed in a Packard γ-counter (Perkin Elmer, Waltham, MA). Results are expressed as 
change in uptake relative to negative uninfected control. All samples were done in triplicate. 
 
4.1.11 Radiopharmaceuticals. 
 
124I, 131I and 99mTcO4 were obtained from MSKCC‘s radiopharmacy. The maximum specific 
activities for the 124I and 131I were ~215-250 uCi/mouse and ~0.5 uCi/well, respectively. 
Activity of 99mTcO4 ranged from 500-900 uCi/mouse. 
 
 
4.2 Mouse Model Experiments 
 
4.2.1 Tumor Therapy Studies and Systemic Toxicity.  
 
All mice were cared for and maintained in accordance with animal welfare regulations under 
an approved protocol by the Institutional Animal Care and Use Committee at Memorial 
Sloan-Kettering Cancer Center, New York and San Diego Science Center, San Diego. 
PANC-1 xenografts were developed in 6- to 8-week-old male nude mice (NCI:Hsd:Athymic 
Nude-Foxn1nu, Harlan) by implanting 2 × 106 PANC-1 cells in PBS subcutaneously in the 
left hindleg. Tumor growth was recorded once a week in 3 dimensions using a digital caliper 
and reported in mm3 using the formula (length × width × [height-5]). When tumors reached 
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100–300mm3, mice were injected Intratumorally (ITly) or Intravnenously (IVly) via the tail 
vein with a single dose of 2 × 106 PFU GLV-1h153 or GLV-1h68 in 100 uL PBS. Animals 
were observed daily for any sign of toxicity, and body weight checked weekly. Animals were 
then euthanized and tumor harvested for viral distribution studies.  
 
4.2.2 In vivo Viral Biodistribution Assays.  
 
Tissue from normal organs (lung, liver, spleen, kidney, brain, testes), as well as from tumor, 
were harvested at 1 and 5 weeks postinjection of virus, weighed, suspended in 500 mL PBS 
containing protease inhibitor, and homogenized for 30 seconds at a speed of 6500 rpm. 
Three to four mice were used per group. After homogenization, samples were subjected to 3 
freeze–thaw cycles. Samples were then centrifuged for 5 minutes at 3000 g at 4°C, 
supernatants collected, and serial dilutions made. Standard plaque assays were performed 
on 24-well plates of confluent CV-1 cells, with all samples assessed in duplicate. The 
remaining mice for each group were followed for 34 days to determine viral effect on tumor 
growth.  
 
4.2.3 Optical Imaging of Pancreatic Tumor Xenografts. 
 
GFP expression of tumors infected with GLV-1h153 was visualized directly using UV light 
fluorescence or utilizing the Maestro 2 system (Cambridge Research and Instrumentation, 
Woburn, MA). For the bioluminescence imaging, animals were analyzed for the presence of 
virus-dependent luciferase activity. For this purpose, mice were injected IV with a 100 uL 
mixture of 5 mL coelenterazine (Sigma; 0.5 mg/mL diluted ethanol solution) and 95 uL of 
luciferase assay buffer (0.5 M NaCl, 1 mM EDTA, and 0.1 M potassium phosphate, pH 7.4). 
The animals were then anesthetized with xyline IP injection and imaged using the ARGUS-
100 (Hamamatsu, Hamamatsu City, Japan). Photons were collected for 1 minute from dorsal 
views of the animals. 
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4.2.4 Histologic Confirmation of GLV-1h153 Infection of Xenografts. 
 
At 1 week post viral injection, animals were sacrificed and the tumors harvested. Tissue 
sections were deparaffinized by serial passages in xylene, then subjected to a graded series 
of ethanol washes before endogenous peroxidase activity was blocked by incubation in a 
50% by volume solution of 3% H2O2/methanol for 10 minutes. Subsequently, slides were be 
pretreated by heating in citrate buffer (10 mm citric acid) for 20 minutes. Following blocking 
of nonspecific binding with blocking serum for 30 minutes, slides were incubated with 
polyclonal antibody produced in rabbits against synthetic peptide AKKIDVQTGRRPYE (the 
C-terminal of A27L vaccinia protein) (custom made by GenScript Corporation, Piscataway, 
NJ) at a dilution of 1:1000 for 30 minutes. Tissue sections were then washed and incubated 
with biotin-conjugated anti-mouse-immunoglobulin for 30 minutes at room temperature, 
followed by incubation with preformed avidin and biotinylated horseradish peroxidase 
macromolecular complex. Diaminobenzidine (DAB) was used as the chromogen, where a 
brownish precipitate would be indicative of VACV immunoreactivity. Slides were 
counterstained with hematoxilyn for 1–5 minutes before mounting.  
 
4.2.5 PET, CT, and γ-Imaging. 
 
All animal studies were performed in compliance with all applicable policies, procedures, and 
regulatory requirements of the MSKCC Institutional Animal Care and Use Committee, the 
MSKCC Research Animal Resource Center. 
 
For the initial IT imaging experiment, 3 groups of 3 animals each, bearing subcutaneous 
PANC-1 xenografts on the left hindleg, were injected ITly with 2 × 107 PFU GLV-1h153, 2 × 
107 PFU GLV-1h68, or PBS. Two days postinjection, ~215 uCi of 124I was administered via 
the tail vein. At hours 1, 2, and 8 after radiotracer administration, 3-dimensional list-mode 
data were acquired using an energy window of 350 to 700 keV, and a coincidence timing 
window of 6 nanoseconds. Imaging was performed using a Focus 120 microPET dedicated 
small-animal PET scanner (Concorde Microsystems Inc, Knoxville, TN). This data was then 
sorted into 2-dimensional histograms by Fourier rebinning. The image data were corrected 
for (a) nonuniformity of scanner response using a uniform cylinder source-based 
normalization, (b) dead time count losses using a single-count rate-based global correction, 
(c) physical decay to the time of injection, and (d) the 124I branching ratio. The count rates in 
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the reconstructed images were converted to activity concentration (%ID/gm) using a system 
calibration factor (MBq/mL per cps/voxel) derived from imaging of a mouse-size phantom 
filled with a uniform aqueous solution of 18F. Image analysis was performed using ASIPro 
(Siemens Pre-clinical Solutions, Knoxville, TN). Four ROIs were manually drawn on each 
tumor and %ID/gm ± SD recorded. The bar (image intensity scale) demonstrates the range 
of uptake intensities, with 100% representing the strongest signal in the image. One mouse 
in the GLV-1h153 group was also imaged with a MicroCAT II MicroCT Scanner (ImTek Inc., 
Knoxville, TN) 8 hours after radiotracer and obtained images fused with those obtained with 
PET that same hour.  
 
For the serial imaging experiment, 2 groups of 2 animals each, bearing subcutaneous 
PANC-1 xenografts on the right hindleg, were injected were injected IVly or ITly with 2 × 106 
PFU of GLV-1h153. Mice were serially imaged at 1 and 4 hours post 124I administration via 
the tail vein at 1, 2, 3, and 5 weeks post viral injection. At week 1 and 2 virus postinjection, 
animals were also imaged 8, 24, 48, and 72hr after radiotracer administration to obtain time-
activity curves. Imaging and data acquisition was done as above. Further, 1 ITly- and 1 IVly- 
injected mouse were also imaged with a MicroCAT II MicroCT Scanner (ImTek Inc., 
Knoxville, TN) 4 hours after radiotracer at week 1 and 2, and obtained images again fused 
with those obtained with PET that same hour. 
 
To investigate if hNIS can also mediate imaging of viral replication with 99mTcO4, 3 groups of 
2 animals each, bearing subcutaneous PANC-1 xenografts on the right hindleg, were 
injected IVly (2 mice) or ITly (2 mice) with 2 × 107 PFU of GLV-1h153, or PBS (2 mice). One 
mouse from each group was imaged with 124I-mediated PET scanning as above, and the 
other imaged with 99mTcO4-mediated γ-scintigraphy 0.5, 1-2, and 3-4 hours after 
99mTcO4 
radiotracer administration. Ventral and dorsal planar images of the in vivo distribution of 
99mTcO4 were simultaneously acquired using the dual-detector gamma camera sub-system of 
the XSPECT small-animal SPECT-CT system (Gamma Medica, Northridge, CA). The 
detectors were fitted with low-energy, high-resolution parallel-hole collimators and images 
acquired over 10 minutes using a 140 keV+10% 99mTcO4 photopeak energy window and a 
56x56 image matrix (pixel size: 2.2x2.2 mm). Images were corrected for non-uniformity of 
response using a measured ―sensitivity map‖; no attenuation or scatter correction was 
applied. The resulting images were parameterized in terms of the percent of the %ID/gm, 
corrected for decay to the time of injection, by applying a system calibration factor (counts 
per second (cps)/pixel/Ci 99mTcO4/ml) determined by imaging a mouse-size (25 ml) 
cylindrical phantom filled with an aqueous solution of 99mTcO4 with a precisely measured 
activity concentration and imaged in the same manner as the mice. 
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4.2.6 Tissue Radiouptake Assay. 
 
Following the initial IT imaging experiment, all mice were sacrificed 8 hours post 124I 
radiotracer injection. Organs (heart, lung, liver, spleen, kidney, thyroid, stomach, muscle, 
blood) and tumors were collected, weighed, and their radioactivity determined with a γ-
counter (Perkin Elmer, Waltham, MA). Data was normalized as described above and also 
expressed as %ID/gm. 
 
4.2.7 Autoradiography. 
 
Three mice bearing subcutaneous PANC-1 xenografts on the right hindleg, were injected 
ITly with 2 × 107 PFU of GLV-1h153 (2 mice) or PBS (1 mouse). Two days after injection, 
~900 uCi of 99mTcO4 was administered via the tail vein. Images were obtained with dual-
detector gamma camera sub-system of the XSPECT small-animal SPECT-CT system 
(Gamma Medica, Northridge, CA).0.5hr after radiotracer administration.  
 
Following imaging of mice, the fluorescent dye Hoechst 33342 trihydrochloride (Sigma) (40 
mg/kg; 1 mg in 100 uL physiological saline) was injected IVly through the tail vein. Five 
minutes after dye injection, animals were sacrificed and tumors excised, embedded in 
mounting medium (O.C.T. Compound, Sakura Finetek, Torrance, CA) and frozen on dry ice. 
Sets of contiguous frozen tissue sections were cut at 6 um thicknesses on a Microm HM500 
cryostat microtome (Microm International GmbH, Walldorf, Germany) and collected on glass 
microscope slides. 
 
To facilitate comparison of the spatial distributions of radiotracer and immunohistochemical 
markers at the microscopic level, digital autoradiography (DAR) was performed on tissue 
sections prepared as described above. Sections were placed in a film cassette against a 
phosphor imaging plate (Fujifilm BAS-MS2325, Fuji Photo Film, Japan). Phosphor plates 
were read out at a resolution of 50 × 50 um on a BAS-1800II Bio-Imaging Analyzer (Fujifilm 
Medical Systems, USA)  
 
Digital images of the distributions of GFP and Hoechst 33342 in tumor sections were 
acquired at 100X magnification using a fluorescence microscope (Nikon Diaphot 300) 
equipped with a computer-controlled motorized stage and digital Coolsnap EZ camera 
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(Photometrics, Tuscon AZ) for image capture After acquisition of fluorescence images, tumor 
sections were stained with hematoxylin and eosin (H&E) and imaged by light microscopy. 
Composite images of whole tumor sections were obtained by stitching individual microscopic 
images using Image-Pro software (Image-Pro plus v. 7.0, MediaCybernetics, Bethesda, 
MD). All images were saved in 8-bit format and manually co-registered using Adobe 
Photoshop (Version 7.0, Adobe Systems, San Jose, CA). 
 
4.2.8 Dosimetry Calculations for Combination Therapy With 131I.  
 
For dosimetry calculations of the serial imaging experiment, four ROIs were manually drawn 
on imaged tumors and averaged, with the mean injected value ± SD recorded. The 124I 
image-derived time-activity concentration data were corrected for radioactive decay to the 
time of injection and fit to exponential functions using least-squares regression281, 282. The 131I 
cumulated activity concentrations (in uCi-hr/gm/uCi 131I administered) were then calculated 
using EXCEL (Microsoft Corp, Redmond, WA) by integrating the fitted time-activity functions, 
incorporating the physical decay constant of 131I (0.0036 /hour). Mean tumor absorbed doses 
(rad/uCi 131I administered) were calculated assuming complete local absorption of the 131I β-
rays (equilibrium dose constant for 131I β-rays: 0.405 gm-rad/uCi-hr) and ignoring the small 
contribution of the 131I γ-rays. In order to treat tumors, an average was obtained for the 
systemically virus-treated mice, with the goal of providing a radiation dose of 2000 rads. For 
a more detailed explanation of dosimetry calculations, please refer to the following paper 
and review 153, 187. 
 
Note that cumulated activities from time-activity data were then obtained by integration from 
the time of administration of the radiopharmaceutical (t = 0) to the time of its complete 
elimination or decay (effective clearance constant, which takes into account both the 
physical (radioactive) decay constant of the radionuclide and its biological clearance 
constant). Time-activity data is the % of administered activity versus time post-
administration. Function parameters of the integration from the time of administration of the 
radiopharmaceutical and the effective clearance constant was iteratively adjusted to 
minimize the sum of the squared differences between the measured data and the 
corresponding calculated (i.e. fitted) value. Analytic integration of the time-activity function 
then yielded the cumulated activity in source region.  
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4.2.9 Combination Therapy With 131I.  
 
For the radiotherapeutic experiment, PANC-1 xenografts were established in the right hind 
leg in five groups of mice: GLV-1h153 (4 mice), GLV-1h153 + 131I (3 mice), GLV-1h68 (4 
mice), GLV-1h68 + 131I (3 mice), and PBS control (5 mice). Based on previous imaging and 
dosimetric calculations, 1 week following IV injection of 2 x 106 PFU of GLV-1h153 or control 
virus GLV-1h68, treated groups were administered 5 mCi of 131I by single IV injection in 
order to achieve an IT dose of around 2000 rads, while the untreated group had 100ul of 
PBS administered. Tumors were measured before administration of 131I and weekly 
thereafter. All mice were weighed weekly and followed up to 5 weeks post virus injection.  
 
4.3 Statistical Analysis 
 
P values were generated for cell culture and tissue radiouptake assay comparisons using 
Dunnett's test, and for imaging radiouptake using the Tukey multiple comparisons test283. 
For treatment experiments, the GraphPad Prism 5.0 program (GraphPad Software, San 
Diego, CA) was used for data handling and analysis. The significance between therapy 
groups was determined via two-way ANOVA with Bonferroni correction. P < 0.05 was 
considered significant.   
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5.0 RESULTS BASED ON SPECIFIC AIMS 
 
5.1 Specific Aim 1: To determine if GLV-1h153 induces the expression of hNIS on 
cancer cell membranes and assess the effects of gene insertion on viral replication.  
 
5.1.1 Construction of the hNIS-encoding GLV-1h153.  
 
The GLV-1h153 construct used in this study was derived from GLV-1h68 by replacing the β-
glucuronidase (gusA) expression cassette at the A56R locus with the hNIS expression 
cassette (SE-hNIS) containing the hNIS cDNA under the control of the VACV synthetic early 
promoter, by homologous recombination in infected cells. The genotype of GLV-1h153 
(Figure 5a) was verified by PCR and sequencing, and the lack of β-glucuronidase 
expression was confirmed by X-GLcA staining (Figure 5b).  
 
 
 
Figure 5a. GLV-1h153 construct. GLV-1h153 was derived from GLV-1h68 by replacing the gusA 
expression cassette at the A56R locus with the hNIS expression cassette through in vivo homologous 
recombination. Both viruses contain RUC-GFP and lacZ expression cassettes at the F14.5L and J2R 
loci, respectively. PE, PE/L, P11, and P7.5 are VACV synthetic early, synthetic early/late, 11K, and 
7.5K promoters, respectively. TFR is human transferrin receptor inserted in the reverse orientation 
with respect to the promoter PE/L. 
 
 
 
Figure 5b. Confirmation of GFP, LacZ, and lack of gusA marker gene expression in GLV-1h153 
infected CV-1 cells. While the gusA gene cassette is expressed in cells infected with parent virus 
GLV-1h68, this has been replaced by the hNIS gene cassette in GLV-1h153, leading to loss of gusA 
expression. 
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5.1.2 GLV-1h153 Replicated Efficiently in PANC-1 Cells. 
 
To evaluate the replication efficiency and effect of hNIS protein expression on VACV 
replication, PANC-1 cells were infected with either GLV-1h153 or its parental virus, GLV-
1h68, at MOIs of 0.01 and 1.0, and the infected cells harvested at 1, 24, 48, and 72 hours 
post infection. The viral titers at each time point were determined in CV-1 cells using 
standard plaque assays. Both GLV-1h153 and GLV-1h68 replicated in PANC-1 cells at 
similar levels, indicating that the hNIS protein did not hinder viral replication within cells. 
GLV-1h153 yielded a 4-log, or 10,000-fold, increase of viral load with an MOI of 0.01 only 72 
hours after infection. Within this time, viral load with an MOI of 0.01 reached the same levels 
as infection with an MOI of 1.0, again indicating efficient replication (Figure 6).  
 
 
Figure 6. Viral proliferation assay of GLV-1h153-in PANC-1 cells. PANC-1 cells were grown in 6-
well plates and infected with GLV-1h153 or GLV-1h68 at an MOI of 0.01 and 1.0. Three wells of each 
virus were harvested at 1, 24, 48, and 72 hours postinfection. GLV-1h153 replicated in a similar 
manner to GLV-1h68, with a 4-log increase in viral load at an MOI of 0.01 by 72 hours, reaching 
similar levels as that  in cells infected with an MOI of 1.0 demonstrating efficient replication of GLV-
1h153. 
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5.1.3 GLV-1h153 Replication was Assessed Via Flow Cytometric Detection of GFP. 
 
GFP expression in cells infected with GLV-1h153 was quantified using flow analysis, and 
was shown to be both time- and MOI-dependent. Adjusting for background, GFP expression 
mimicked the viral replication growth curve, with GFP expression in cells infected at an MOI 
of 0.01 reaching similar levels to an MOI of 1.0 by 72 hours (Figure 7a). Further, >70% of 
live cells expressed GFP at an MOI of 5.0 at 24hrs postinfection (Figure 7b).  
 
 
Figure 7a. Flow cytometry of time-dependent GFP expression. GFP was quantified via flow 
cytometry in PANC-1 cells infected with GLV-1h153 at MOIs of 1.0 and 0.01 and was shown to be 
MOI dependent. GFP expression mimicked the viral replication growth curve, with expression in the 
MOI 0.01 infected cells reaching similar levels as the MOI of 1.0 by 72 hours after infection.  
 
 
Figure 7b. Flow cytometry of MOI-dependent GFP expression. GFP expression was quantified via 
flow cytometry in PANC-1 cells infected with an MOI of 0.01, 0.1, 0.5, 1.0 2.0, and 5.0 at 24 hours 
after infection, and was shown to be MOI-dependent. >70% of live cells expressed GFP at an MOI of 
5.0 at 24hrs postinfection. 
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5.1.4 GLV-1h153 successfully expressed hNIS mRNA and Protein in Infected Cells. 
 
To confirm production of hNIS mRNA by GLV-1h153-infected PANC-1 cells, cells were 
infected at an MOI of 5.0 and mRNA isolated for analysis with Affymetrix chips. mRNA in 
cells had an almost 2000-fold increase by only 6 hours after infection, and a >5000-fold 
change by 24 hours (P<0.05) (Figure 8a). To show hNIS protein expression by GLV-1h153, 
PANC-1 cells were mock infected or infected with GLV-1h153 or parental virus GLV-1h68 at 
MOIs of 0.1, 1.0, and 5.0 and harvested 24 hours after infection. Production of the hNIS 
protein was successfully detected by Western blot between 75 and 100 kDa, with an 
increasing concentration of protein at higher MOIs (Figure 8b).  
 
 
Figure 8a. Assessment of hNIS mRNA expression in GLV-1h153-infected PANC-1 cells. 
Microarray analysis of cells infected with an MOI of 5.0 of GLV-1h153 yielded an almost 2000-fold 
increase by 6 hours and an almost 5000-fold increase by 24 hours in hNIS mRNA production as 
compared to noninfected control.  
 
 
Figure 8b. Assessment of hNIS protein expression in GLV-1h153-infected PANC-1 cells PANC-
1 cells were either mock infected or infected with GLV-1h68 at an MOI of 1.0 or infected with GLV-
1h153 at an MOI of 1.0 or 5.0 for 24 hours. The hNIS protein was detected by Western blot analysis 
using monoclonal anti-hNIS antibody. Only GLV-1h153-infected cells expressed the hNIS protein, but 
cells either mock infected or infected with GLV-1h68 did not. The molecular weight marker bands (in 
kDa) are shown on the left.  
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5.1.5 The hNIS Protein was Localized at the Cell Membrane of PANC-1 Cells.  
To determine whether the hNIS protein expressed by GLV-1h153 was successfully 
transported and inserted on the cell membrane, PANC-1 cells were infected with GLV-1h153 
and fixed with 3.7% paraformaldehyde. The hNIS protein was visualized using a monoclonal 
anti-hNIS antibody that recognizes the intracellular domain of the protein. As shown in 
Figure 9, mock- or GLV-1h68-infected cells (as demonstrated by GFP expression) did not 
show hNIS protein expression, whereas the hNIS protein in cells infected with GLV-1h153 
was readily detectable by immunofluorescence microscopy, and appears to be localized at 
the cell membrane. 
 
Figure 9. Immunofluorescence of hNIS protein location in GLV-1h153-infected PANC-1 cells 
PANC-1 cells were mock-infected or infected with GLV-1h68 or GLV-1h153 at a MOI of 1.0 for 24 
hours. The hNIS protein was detected by immunofluorescence microscopy using monoclonal anti-
hNIS antibody. Mock- or GLV-1h68-infected cells (as demonstrated by GFP expression) did not 
express the hNIS protein, whereas the hNIS immunoreactivity was readily detectable on the cell 
membrane of PANC-1 cells infected with GLV-1h153. 
 
5.1.6 GLV-1h153-Infected PANC-1 Cells Showed Enhanced Dose- and Time-Dependent 
Uptake of Carrier-Free Radioiodide. 
 
To establish that the hNIS symporter was functional, cells were mock infected or infected at 
an MOI of 1.0 with GLV-1h153 and GLV-1h68, then treated with 131I at various times after 
infection. GLV-1h68-infected cells were treated at 24 hours postinfection. Normal rat thyroid 
cell line PCCL3 was used as a positive control. PANC-1 cells infected with GLV-1h153 
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showed a >70-fold increased radiouptake compared with negative control at 24 hours post 
infection (P<0.001), compared to 2.67 and 1.01 with MOIs of 0.1 and 0.01, respectively. This 
increased uptake correlated with peak GFP expression (Figure 10, left panel). Moreover, 
when cells were treated with NaClO4, a competitive inhibitor of hNIS, radiouptake decreased 
in GLV-1h153-treated cells, from a 70- to a 1.14-fold difference at an MOI of 1.0, indicating 
hNIS-specific radiouptake. Radiouptake was also shown to be time-dependent, and again 
correlated with GFP expression, with a decrease of both radiouptake and GFP expression 
by 48hrs. (Figure 10, left panel). 
 
                       
                    
Figure 10. Assessment of cell culture 
131
I radiouptake of GLV-1h153-infected PANC-1 cells. 
PANC-1 cells were infected with an MOI of 0, 0.01, 0.1, and 1.0 of GLV-1h153 and MOI of 1.0 of 
GLV-1h68. PCCL3 was used as a positive control. Twenty-four hours after infection, a >70-fold 
enhanced radiouptake was seen at an MOI of 1.0 as compared to an MOI of 0 in GLV-1h153. Uptake 
was MOI-dependent and hNIS-specific (as shown with blocking with competitive inhibitor of hNIS, 
NaClO4). Maximum radiouptake with an MOI of 1.0 24 hrs after infection corresponded to maximum 
GFP expression (left panel). PANC-1 cells were mock infected or infected with an MOI of 1.0 of GLV-
1h153 and MOI of 1.0 of GLV-1h68 (harvested at 24 hours post infection). Radiouptake was time-
dependent and correlated with GFP expression, with a decrease of radiouptake and GFP expression 
by 48hrs (right panel). 
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5.2 Specific Aim 2: To establish that GLV-1h153 specifically kills pancreatic cancer 
cell line PANC-1, and is safe when administered in animal models.  
 
 
5.2.1 Cytotoxicity Assay. 
 
To investigate whether expression of hNIS would affect cytolytic activity of VACV in cell 
cultures, PANC-1 cells were mock-infected or infected with GLV-1h68 or GLV-1h153 at an 
MOI of 0.01 and 1.0. Viral cytotoxicity was measured every other day for 7 days. The 
survival curves for GLV-1h68 and GLV-1h153 were almost identical at both MOIs, indicating 
a similar cytopathic effect of both viruses in a time- and dose-dependent fashion (Figure 
11a). By day 11, More than 60% cell kill was achieved with an MOI of 1.0 as compared to 
control. Cytotoxicity again correlated with GFP expression (Figure 11b). 
 
 
Figure 11a. GLV-1h153 infection and killing in cell culture. a. PANC-1 cells were infected by 
various GLV-1h153at MOIs of 0.01, 0.1, and 1.0. Cell viability was determined via lactate 
dehydrogenase assays, and was set at 100% before infection. GLV-1h153 infected and was cytotoxic 
at various MOIs, with less than 20% survival of cells as compared to control at an MOI of 1.0 by day 
9. The values are the mean of triplicate samples, and bars indicate SD.  
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Figure 11b. Microscopy of GLV-1h153 infection and killing in cell culture. GFP expression, 
shown here at an MOI of 1.0, is time-dependent with abundant GFP expression by day 3. Phase 
overlay pictures shows gradual cell death and thus decline of GFP expression by day 7. Closer 
examination of infected cells reveals loss of normal morphology and cell progressive cell detachment. 
 
5.2.2 Tumor Therapy Studies and Systemic Toxicity.  
 
To establish cytolytic effects of GLV-1h153 in animal models, mice bearing PANC-1 hindleg 
xenografts were infected IT or IV with GLV-1h153 or GLV-1h168, or mock-treated with PBS. 
While the tumors treated with PBS continued to grow, GLV-1h153-treated tumors occurred 
in three distinct phases: growth, inhibition, and regression (Figure 12a). The mean relative 
size of tumors treated with GLV-1h153 was significantly smaller than untreated control 
tumors, with differences beginning as early as day 13 (P < 0.01), and continuing till day 34 
after virus or PBS control administration (P < 0.001). By day 34, there was an over 4-fold 
difference between control and IV tumor volumes, a >6 fold difference in the IT group. 
Furthermore, there were no significant adverse effects seen with regard to body weight, with 
the IT group gaining weight as compared to control with statistically significant results by day 
34 (P < 0.001) (Figure 12b). 
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Figure 12a. GLV-1h153-mediated killing of PANC-1 tumor xenografts. Two × 10
6
 PFU of GLV-
1h153 or GLV-1h68, or PBS were injected IVly or ITly into nude mice bearing S.C. PANC-1 tumors 
(~100 mm
3
). GLV-1h153 slowed growth and regressed pancreatic tumor xenografts from initial tumor 
volume when injected both ITly and IVly starting at day 13. The values are a mean of 4-5 mice, with 
bars indicating SEM.  
 
.  
Figure 12b. Body weights of animals post GLV-1h153 treatment. GLV-1h153 treatment of 
pancreatic tumor xenografts did not have adverse effects on body weight at 5 weeks postinjection, 
with the IT group even gaining weight compared to control. 
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5.2.3 Viral Biodistribution Assays.  
 
To assess viral biodistribution in animal models, GLV-1h153 particles were recovered from 
tumor tissues of virus-treated animals at 1 and 5 weeks in the order of 109 virus particles per 
gram tissue in both the IT and IV groups (3-4 mice per group per time point). Only trace 
amounts of virus were detected in the spleen and lungs for the IT and IV groups and in the 
spleen for the IT group at 1 week. By 5 weeks, virus replication persisted at almost 109 virus 
particles per gram of tissue in the tumors, while residual viral particles were mostly cleared in 
other organs with only trace amounts remaining in the lung and kidney in the IV and IT 
groups, respectively (Figure 13).  
 
 
Figure 13. GLV-1h153 biodistribution in animal models. GLV-1h153 and GLV-1h68 particles were 
recovered from tumor tissues of virus-treated animals at 1 and 5 weeks post IT or IV injection of virus 
in the order of 10
9
 viral particles in both groups (log scale, 3-4 mice per group per time point). Trace 
amounts of virus were detected in the testes, spleen, kidney and lungs for both viruses and for both 
the IV and IT group at 1 week. By 5 weeks, virus replication persisted at almost 10
9
 virus particles per 
gram of tissue in the tumors, while residual viral particles were cleared in most organs. 
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5.2.4 Histologic and Optical Confirmation GLV-1h153 Infection of Tumor Xenografts. 
 
To confirm virus presence in tumors, 2 animals from GLV-1h153 and GLV-1h68 IT and IV 
groups, as well as PBS controls, were sacrificed 1 week after treatment. All tumors treated 
with either GLV-1h153 or GLV-1h68 stained positive for vaccinia A27L antigen, yielding a 
brownish precipitate compared to the blue-purple hematoxylin background seen with 
uninfected areas and control tumors. Tumors injected ITly showed more homogenous areas 
of brown precipitation as compared to a more dispersed pattern in the IV-infected group, 
which is explained by the systemic rather than local spread of virus within the tumor. Tumors 
infected with GLV-1h153 expressed GFP, which persisted 5 weeks after injection. 
Furthermore, virus was detectable in virus-infected tumors by bioluminescence imaging of 
luciferase activity 1 week after viral administration (Figure 14). 
 
 
Figure 14. Histologic and optical detection of viral replication using vaccinia marker genes. 
GFP expression was monitored at 1, 3, and 5 weeks after GLV-1h153 injection and persisted 5 weeks 
posttreatment. GLV-1h153 was also detected via RLuc bioluminescence imaging 1 week 
posttreatment. Presence of GLV-1h153 in tumors was confirmed histologically, shown here with the 
brownish precipitate against vaccinia A27L antigen in the IT and IV groups at 400x magnification. 
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5.3 Specific Aim 3: To determine if GLV-1h153-induced hNIS expression facilitates 
intracellular uptake of radioiodide, thus enabling imaging of tumor and viral therapy. 
 
 
5.3.1 GLV-1h153 Enhanced Radiouptake in Tumor Xenografts and was Imaged Via 
PET. 
 
After successful cell culture radiouptake studies, the feasibility of using GLV-1h153 in 
combination with carrier-free 124I radiotracer to image infected PANC-1 tumors was 
investigated. hNIS protein expression in the PANC-1 tumor-bearing animals after GLV-
1h153 administration was visualized by 124I-PET. Carrier free 124I was IVly administered 48 
hours after IT virus injection and PET imaging was performed 1, 2, and 8 hours after 
radiotracer administration. Tumor radioactivity values (%ID/gm) were measured and 
compared to background. The maximum average levels of radioactivity in GLV-1h153-
injected tumors were 3.82 ± 0.46 1 hour after radiotracer administration, whereas GLV-1h68- 
and PBS-injected tumors could not be visualized, and therefore were not significantly above 
background (P< 0.001). The stomach and thyroid were also imaged due to native NIS 
expression, and the bladder due to tracer excretion (Figure 15). 
 
 
Figure 15. PET imaging of enhanced radiouptake in GLV-1h153-infected PANC-1 xenografts.  
Two × 10
7
 PFU of GLV-1h153, GLV-1h68, or PBS was injected ITly into PANC-1 hindleg tumor-
bearing mice. 
124
I PET scanning was obtained 48 hours after infection and 1 hour after radiotracer 
administration. GLV-1h153-infected PANC-1 tumors were easily visualized, while no enhanced signal 
was seen in the PBS- or GLV-1h68 injected tumors. Stomach and thyroid were also imaged due to 
native NIS expression, and the bladder due to tracer excretion  
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5.3.2 GLV-1h153-Enhanced Radiouptake Was Retained In PANC-1 Tumor Xenografts. 
 
When the ITly-injected mice were imaged serially over 1, 2, and 8 hours, absolute activity in 
tumors declined. However, the ratio of activity to background increased from 9.11 ± 1.48 
(P<0.001) to 25.0 ± 7.05 (P<0.01) (Figure 16b and 16c). 
 
 
Figure 16a. Timing characteristics of radiouptake in GLV-1h153-infected PANC-1 xenografts. 
Two × 10
7
 PFU of GLV-1h153 or PBS was injected ITly into PANC-1 hindleg tumor-bearing mice. 
124
I-
PET scanning was performed 48 hours after infection and 1, 4, and 8 hrs after radiotracer 
administration.  
 
Figure 16b. Ratio of radiouptake to background in PANC-1 xenografts. Although absolute 
radiouptake decreased between 1 and 8 hours post radiotracer administration, ratio of uptake versus 
background steadily increased, showing successful retention of radiotracer in tumors.  
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5.3.3 GLV-1h153-Mediated Tissue Radiouptake Correlated Well With Quantative PET. 
Enhanced radiouptake in ITly GLV-1h153-injected tumors to other organs as well as GLV-
1h68- and PBS-injected tumors was confirmed in ITly-injected mice (2-3 mice per group) via 
tissue radiouptake assay at 8 hours post radiotracer administration. The activity in GLV-
1h153-infected tumors correlated well with PET images, at 1.71 ± 0.30 (P<0.001 compared 
to both PBS and GLV-1h68 groups) and 1.84 ± 0.42 (P<0.01 also compared to both PBS 
and GLV-1h68), respectively, whereas tumors in the control groups were again not above 
background (Figure 17).  
.  
Figure 17. Tissue radiouptake assay. Enhanced radiouptake in tumors infected with GLV-1h153 
compared to GLV-1h68 and PBS 8 hrs after radiotracer injection was confirmed via tissue radiouptake 
assays and correlated well with quantitative PET. Native NIS expression in the stomach also leads to 
enhanced radiouptake in all groups, but only in the GLV-1h153-mediated NIS expression in infected 
tumors. 
 
5.3.4 GLV-1h153 Facilitated Serial Monitoring Of Systemic and IT Viral Therapy. 
 
After establishing that GLV-1h153 enhances radiouptake in animal models, is detected by 
PET, and induces radiouptake retention, GLV-1h153 facilitation of serial imaging and 
monitoring of both IT and systemic viral therapy was then determined. Two mice were 
injected either ITly or IVly with 2 x 106 PFU of virus, which was the same dose used in the 
therapeutic and biodistribution assay experiments. Mice were imaged at 1, 2, 3, and 5 weeks 
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post virus injection and 1 and 4 hours post radiotracer administration to determine 
radiouptake in tumors. At week 1 and 2 post virus injection, mice were also imaged at 1, 4, 
8, 24, 48, and 72 hours post injection in order to calculate absorbed doses in the tumor with 
dosimetry. As can be seen in the Figure 18, PET imaging readily detected virus replication in 
tumors as late as 5 weeks postinjection. While the GFP signal continued to be strong, hNIS-
mediated radiouptake peaked at around 2 weeks post virus injection, and gradually declined 
by week 3 and 5. This is despite a persistent strong GFP signal by 5 weeks.  
 
 
Figure 18. Serial monitoring of GLV-1h153 treatment of PANC-1 tumor xenografts. Two × 10
6
 
PFU of GLV-1h153 was injected IVly or ITly into PANC-1 right hindleg tumor-bearing mice. 
124
I PET 
scanning was obtained 1, 2, 3, and 5 weeks post virus injection, and 4 hours post radiotracer 
administration at each week. hNIS-mediated enhanced radiouptake in GLV-1h153-infected tumors 
could be serially monitored, being strong at week 1 and 2 post virus injection, with gradual declined by 
week 3 and 5 despite strong GFP expression remaining. 
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5.3.5 GLV-1h153 Tumor Infection was Confirmed Via GFP, Bioluminescence, and CT-
PET. 
 
GLV-1h153 presence in tumors, mediating radiouptake, was confirmed via GFP, 
bioluminescense, and CT-PET imaging 1 and 2 weeks post viral injection in both the IV and 
IT groups. As can be seen in Figure 19, all reporter genes were detectable, and fusion of 
PET and CT images correlated enhanced signals anatomically to the location of the tumor, 
stomach, bladder, and thyroid. 
 
 
Figure 19. GLV-1h153 reporter genes were detectable in PANC-1 xenografts. GFP, 
bioluminescence, and hNIS signal could all be detected in GLV-1h153-infected tumors. Fusion of PET 
and CT images correlated uptake signal anatomically to the location of the thyroid, stomach, bladder, 
and tumor, while GFP and bioluminescense signals located only to the tumor. 
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5.3.6 Correlation of PET Signal Pattern With Tumor Regression. 
 
When comparing PET signal intensity with tumor growth patterns in mice over 5 weeks, 
enhanced radiosignal appears to correlate with initial tumor growth, growth retardation, and 
eventual regression. The PET signal remained strong during the first 2 weeks postinjection 
of virus, which reflected initial tumor growth. However, when tumor growth began entering a 
plateau phase, PET signal began to decrease and almost disappear by week 5, when 
tumors have entered the regression phase. Interestingly, M3‘s tumor took longer to regress, 
and maintained a signal up to 5 weeks post virus injection (Figure 20). 
 
 
 
Figure 20. PET signal intensity and tumor growth charactersitics. The PET signal remained 
strong during initial tumor growth for serially imaged mice. When tumor growth entered a plateau 
phase, PET signal began to decrease. By week 5, tumors have entered the regression phase, and 
PET signal almost disappears.  
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5.3.7 Histology of GLV-1h153-Treated Tumors 5 Weeks Postinjection. 
 
Histology of serially imaged tumors confirmed wide areas of necrosis and inflammatory 
infiltrate (Figure 21). Necrotic areas were more homogenous in the IVly-treated group, 
whereas „islands―of necrosis surrounded by inflammatory infiltrate was seen in the IT group, 
reflecting virus route of administration. Interestingly, no viable cells were detected 
histologically in all mice tumors except M3, which retained some viable tumor proliferation 
activity.  
 
 
Figure 21. Histology of GLV-1h153-treated tumors 5 weeks postinjection. All mice were 
sacrificed 5 weeks post virus injection and serial imaging, and tumors harvested for histology. H&E 
staining of imaged tumors confirmed wide areas of necrosis and inflammatory infiltrate. No viable cells 
were detected histologically in all mice tumors except M3, which retained some viable tumor 
proliferation activity.  
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5.3.8 Viral Dose Comparisons. 
 
To investigate the effects of viral dose administered on the hNIS-mediated PET signal, 2 
groups of 1 animal each, bearing subcutaneous PANC-1 xenografts on the right hindleg, 
were injected IVly (2 mice) or ITly (2 mice) with 2 x 107 or 2 x 106 PFU of GLV-1h153. Mice 
were imaged with 124I-mediated PET scanning as above at 4 hours post radiotracer injection. 
IT injection of 2 x 107 PFU caused a weaker initial (Figure 22a) and more rapid loss of signal 
(Figure 22b) than the IT injection with 2 x 106. However, injection IVly with 2 x 107 PFU lead 
to a higher initial uptake (Figure 22a), although this also rapidly decreased over 5 weeks 
post viral injection (Figure 22b). This suggests that virally-mediated tumor cell death and/or 
necrosis, and thus hNIS functionality, is dose-dependent. 
 
 
Figure 22a. Imaging of viral dose comparisons. Mice were injected IVly or ITly with 2 x 10
7
 or 2 x 
10
6
 PFU of GLV-1h153 and imaged with 
124
I-mediated PET 4 hours post radiotracer injection. The IT 
injection of 2 x 10
7
 PFU caused a weaker initial signal than the IT injection with 2 x 10
6
. However, 
injection IVly with 2 x 10
7
 PFU lead to a strong initial signal similar to the 2 x 10
6
 group.  
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Figure 22b. Serial PET signal intensity and tumor growth characteristics of different viral 
doses. IT injection of 2 x 10
7
 PFU causes a weaker initial and more rapid loss of signal than the IT 
injection with 2 x 10
6
. Injection IVly with 2 x 10
7
 PFU lead to a higher initial uptake which also rapidly 
decreased over 5 weeks post viral injection.  
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5.3.9 GLV-1h153 can be Detected Via 
99mTcO4-Mediated γ-Scanning. 
 
To determine if GLV-1h153-mediated hNIS transfer can also be detected with 99mTcO4, 3 
groups of 2 animals each, bearing subcutaneous PANC-1 xenografts on the right hindleg, 
were injected IVly (2 mice) or ITly (2 mice) with 2 × 107 PFU of GLV-1h153, or PBS (2 mice). 
One mouse from each group was imaged with 124I-mediated PET scanning and the other 
imaged with 99mTcO4-mediated γ-scanning. Viral-mediated uptake was successfully detected 
and easily visualized with 99mTcO4, although image resolutions were less than 
124I-mediated 
PET scanning (Figure 23). Like the PET images, uptake was also noted in the bladder due 
to radiotracer excretion, as well as the thyroid and stomach due to intrinsic hNIS expression.  
 
Figure 23. Detection of GLV-1h153 with TcO4-mediated γ-scintigraphy. Three groups of 2 
animals each bearing subcutaneous PANC-1 xenografts on the right hindleg, were injected IVly (2 
mice) or ITly (2 mice) with 2 × 107 PFU of GLV-1h153, or PBS (2 mice). Mice were imaged 
124
I-
mediated PET or 
99m
TcO4-mediated γ-scanning. Viral-mediated uptake was successfully detected and 
easily with 
99m
TcO4-mediated γ-scintigraphy, 
124
I-mediated PET scanning. Uptake was also noted in 
the bladder due to radiotracer excretion, as well as the thyroid and stomach due to intrinsic NIS 
expression. 
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5.3.10 hNIS-Mediated Uptake Requires Presence of Virus and Adequate Blood Flow. 
 
To determine what conditions are therefore needed for adequate GLV-1h153-mediated 
radiouptake and retention in tumors, autoradiography was performed. Using 99mTcO4 and γ-
scintigraphy, 2 mice with tumors injected ITly with GLV-1h153 and 1 control mouse injected 
with PBS were imaged 2 days posttreatment. Mice were then IVly injected with hoechst dye 
to stain for blood flow, and tumors then harvested and sectioned in order to determine 
regions of uptake. The short viral treatment duration and localized IT administration enabled 
„hotspots― of radiouptake in the tumor, which when compared to adjacent slices for GFP and 
hoechst staining revealed the need for both blood flow and GLV-1h153 infection to be 
present. Areas that lacked GFP (and thus virus), and areas noted to be necrotic on H&E 
staining with lack of blood flow did not support uptake. No uptake was noted in control 
tumors despite adequate blood flow (Figure 24a and 24b). 
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Figure 24a. Autoradioraphy of tumor samples injected with GLV-1h153. Using 
99m
TcO4 and γ-scintigraphy, 2 mice with tumors injected ITly 
with GLV-1h153 and 1 control mouse were imaged 2 days posttreatment. Mice were then injected with hoechst dye to stain for blood flow and 
tumors harvested and sectioned in order to determine regions of uptake. „Hotspots― of radiouptake in tumors (T1 and T2) correlated with GFP and 
hoechst staining revealing the need for both blood flow and virus to be present. Areas that lacked GFP (and thus virus), and areas noted to be 
necrotic on H&E stain with lack of blood flow did not support uptake. No uptake was noted in control tumors despite adequate blood flow (T3).  
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Figure 24b. Enlarged merged sections correlating areas of uptake hotspots with GFP and hoechst dye. Areas that lacked GFP (and thus 
virus) and areas noted to be necrotic on H&E stain with lack of blood flow (and thus hoechst staining) did not support uptake. No uptake was noted 
in control tumors despite adequate blood flow. 
 
Uninfected Control T1 T2
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5.4 Specific Aim 4: To determine if combination therapy with GLV-1h153 and 131I 
produces additive or synergistic tumor killing. 
 
 
5.4.1 Time-Activity Curves. 
 
To calculate absorbed doses in tumors, time-activity concentration data was generated from 
previous mice injected IVly or ITly with 2 x 106 PFU of GLV-1h153. Mice were serially imaged at 
1, 4, 8, 24, 48, and 72 hours after radiotracer administration at 1 and 2 weeks post viral 
injection. At 1 week post virus injection, 124I Uptake was maximal at 1 hour post radiotracer 
injection at an average of 8.39 ± 1.23 %ID/gm for the IV group and 10.81 ± 1.10 for the IT 
group. Uptake exponentially declined over 72 hours (Figure 25a and 5b). Interestingly, image 
and time activity data were similar in week 2, with a slight increased maximal 1 hour uptake of 
10.14 ± 1.43 %ID/gm for the IV group and decreased maximal uptake of 8.05 ± 0.01 for the IT 
group (Figure 26a and 26b). 
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Figure 25a. Timing characteristics of radiouptake in GLV-1h153-infected PANC-1 xenografts 1 
week post virus injection. Image signal was strongest 1 hour postinjection and gradually declined over 
72 hours. 
 
Figure 25b. Time activity concentration data generated from image-derived radiouptakes 1 week 
post virus injection. Time activity concentration data derived from serial images at 1 week post virus 
injection revealed a maximal radiouptake at 1 hour post radiotracer injection, with an exponential 
decrease in uptake over 72 hours.  
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Figure 26a. Timing characteristics of radiouptake in GLV-1h153-infected PANC-1 xenografts 2 
weeks post virus injection. Image signal was strongest 1 hour postinjection and gradually declined over 
72 hours. 
 
Figure 26b. Time activity concentration data generated from image-derived radiouptakes 2 weeks 
post virus injection. Time activity concentration data derived from serial images at 2 weeks post virus 
injection revealed a maximal radiouptake at 1 hour post radiotracer injection with an exponential decrease 
in uptake over 72 hours.  
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5.4.2 GLV-1h153 has Potential to Deliver Targeted and Therapeutic Radioiodine to 
Tumors. 
 
To calculate absorbed doses in tumors, image-derived time-activity concentration data obtained 
above were corrected for radioactive decay to the time of injection and fit to exponential 
functions using least-squares regression. The 131I cumulated activity concentrations (in uCi-
hr/gm/uCi 131I administered) were then calculated by integrating the fitted time-activity functions, 
incorporating the physical decay constant of 131I. For the IV group, the average absorbed dose 
was 416.83 ± 130.68 rad/mci at week 1 and 514.57 ± 22.70 at week 2 post virus injection. The 
For the IT group, average absorbed doses were 387.02 ± 104.60 rad/mci at week 1 and 352.88 
± 95.45 at week 2. The absorbed dose at week 1 post virus injection appears higher in the IV 
group despite a lower maximal radiouptake, signifying longer retention time in the tumor. An 
estimated 2000 rad dose is required for a therapeutic effect to be seen in tumors. Therefore, in 
order to achieve a rad dose of 2000 in the IV-treated group 1 week post injection, around 4-5 
mci of 131I is required. Table 5 shows a summary of uptakes, effective ½ lives, and absorbed 
calculated doses in tumors. 
.  
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Table 5. Dosimetric calculations of radiouptake in tumor xenografts. 
Hour 1 2 1 2 1 2 1 2
1 9.26 11.14
4 8.10 9.95
8 5.86 8.33
24 1.75 0.84
48 0.20 0.09
72 0.07 0.04
1 7.52 9.13
4 4.55 7.84
8 2.43 5.71
24 1.18 1.12
48 0.50 0.12
72 0.10 0.05
1 11.58 8.04
4 6.86 4.99
8 2.53 3.15
24 0.31 0.41
48 0.04 0.06
72 0.03 0.03
1 10.03 8.05
4 8.89 6.73
8 5.55 5.01
24 1.24 1.09
48 0.18 0.13
72 0.08 0.05
124I
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M1 7.39 65.08 489
131I
Effective 1/2 time 
(hr) 
Absorbed 
dose 
(rad/mci)
Effective 1/2 time 
(hr) 
Absorbed 
dose 
(rad/mci)
Effective 1/2 time 
(hr) 
Absorbed 
dose 
(rad/mci)
Effective 1/2 time 
(hr) 
Absorbed 
dose 
(rad/mci)
Week 1 Post Virus Injection Week 2 Post Virus Injection
Uptake
Dosimetry
Uptake 
Dosimetry 
124I 131I
M2 2.54 15.17 312 2.58 16.46 324
7.68 98.21 509
7.39 65.08 487 7.68 98.21 499
5.82 73.99 5315.65 53.48 520
98.20 285
M4 4.75 16.57 452 4.87 18.12 461 7.39
98.21 313 4.63 65.08 273 4.74M3 3.35 65.08 304 3.41
65.08 407 7.68 98.21 420
2
e
6
 P
FU
s 
In
tr
at
u
m
o
ra
l
104 
 
5.4.3 Combining GLV-1h153 and Radioiodine Mediates Greater Therapeutic Efficacy. 
 
For the combination therapy experiment, PANC-1 xenografts were established in the right 
hind leg in five groups of mice: GLV-1h153, GLV-1h153 + 131I, GLV-1h68, GLV-1h68 + 131I, 
and PBS control. Based on previous imaging and dosimetric calculations, one week 
following IV injection of 2x106 PFU of GLV-1h153 or control virus GLV-1h68, treated groups 
were administered ~5 mCi of 131I by a single IV injection in order to achieve an absorbed 
dose of around 2000 rads in tumors. Control tumors continued to grow, and while GLV-
1h153, GLV-1h68, and GLV-1h68 +131I mediated similar therapy effects, the GLV-1h153 
+131I group seemed to have more rapid and greater tumor regression (Figure 27). This effect, 
however, was not statistically significant. 
 
 
Figure 27. Combination therapy with GLV-1h153 and 
131
I. For the radiotherapeutic experiment, 
PANC-1 xenografts were established in the right hind leg in five groups of mice: GLV-1h153 (4 mice), 
GLV-1h153 + 
131
I (3 mice), GLV-1h68 (4 mice), GLV-1h68 + 
131
I (3 mice), and PBS control (5 mice, 
not shown in graph). One week following IV injection of 2x10
6
 PFU of GLV-1h153 or control virus 
GLV-1h68, treated groups of mice were administered 5 mCi of 
131
I by a single IV injection. GLV-
1h153, GLV-1h68, and GLV-1h68 +
131
I mediated similar therapy effects, while the GLV-1h153 +
131
I 
group seemed to have more rapid and greater tumor regression.    
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6.0 DISCUSSION 
 
Twelve million people worldwide will be diagnosed with cancer this year, and 7 million will 
die from cancer-related causes despite advances in conventional therapies1. Therefore, 
developing novel therapies, which may also work synergistically in combination with 
conventional treatment options, is vital. Oncolytic viral therapies have made their mark on 
the cancer research world as another potential therapeutic option, with the possible 
advantages of lessening side effects as well as strengthening treatment efficacy due to 
higher tumor selectivity9. Results have been so promising that oncolytic viral treatments 
have now been approved for clinical trials in several countries280, and the first oncolytic viral 
therapy has now been marketed as a treatment for head and neck cancers in China284. 
Pancreatic cancer in particular is a deadly disease with poor response single agent or 
combination chemotherapies, and explains the active investigation underway seeking novel 
therapeutic strategies for this disease6, 7.  
 
Several clinical trials are underway to assess the effects of viral therapies280. However, 
future clinical studies may benefit from the ability to noninvasively and serially identify sites 
of viral targeting and to measure the level of viral infection in order to provide important 
safety, efficacy, and toxicity information135, 285, 286. Such real-time tracking would also provide 
useful viral dose and administration schedule information for optimization of therapy and 
would obviate the need for multiple and repeated tissue biopsies. 
 
VACV is arguably the most successful biologic therapy agent, since versions of this virus 
were given to millions of humans during the smallpox eradication campaign46. More recently, 
engineered VACVs have also been successfully used as direct oncolytic agents, capable of 
preferentially infecting, replicating within, and killing a wide variety of cancer cell types9, 43, 72, 
96, 97, 110, 287-290. Vaccinia displays many of the qualities thought necessary for an effective 
oncolytic antitumor agent77, 289, 291. In particular, the large insertional cloning capacity allows 
for the inclusion of several functional and therapeutic transgenes. With the insertion of 
reporter genes not expressed in uninfected cells, viruses can be localized and the course of 
viral therapy monitored in patients. 
 
One such promising virus strain is GLV-1h68. This strain has shown efficacy in the treatment 
of breast tumors43, mesothelioma96, pancreatic cancers72, anaplastic thyroid cancer97, 287, 
and melanoma110, and is currently being tested in phase I human trials with substantial data 
showing promising safety and therapeutic responses280. 
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This work centers on the generation of a novel recombinant VACV, GLV-1h153, derived 
from GLV-1h68, which has been engineered for specific targeted treatment of cancer and 
the additional capability of facilitating noninvasive imaging of tumors and metastases. To 
date, GLV-1h153 is the first vaccinia oncolytic virus expressing the hNIS protein that can 
efficiently eliminate tumors and simultaneously facilitate deep tissue imaging of infected 
tumors.  
 
The reporter gene chosen for insertion into GLV-1h153 was based on the already successful 
PET and SPECT imaging characteristics of the hNIS and carrier free radioiodine reporter 
imaging system. hNIS is an intrinsic plasma membrane protein which mediates the active 
transport and concentration of iodide in the thyroid gland cells and some extra-thyroidal 
tissues166, 167, 292, 293. It is also one of several human reporter genes currently being used in 
preclinical studies and has even been used in clinical studies imaging adenoviral-mediated 
hNIS transfer in prostate cancer269, 280. hNIS gene transfer via viral vector may allow infected 
tumor cells to concentrate several radionuclide probes which have long been approved for 
human use. The hNIS‘s transporter based system also allows signal amplification rather 
than, for example, a 1:1 binding relationship with radiolabelled ligands as seen with the 
human somatostatin receptor hSSTR2120. Furthermore, imaging with hNIS has been 
comparable to the commonly used HSV1-tk reporter gene179 and correlated with 99mTcO4180.  
 
Oncolytic viruses encoding hNIS that have been investigated to date include several 
adenoviruses263, 264, 266-268 and measles viruses270-276, as well as a vesicular stomatitis virus 
(VSV)278. Results have been promising; however, there are several disadvantages to each 
strain. Although it can transduce a broad spectrum of cells with high infection efficiency, lack 
of replication and tumor transduction capacity due to gene insertion have limited clinical 
application of adenoviruses. Uptake in tumors has required high MOIs of initial virus 
administration, and imaging signals in tumors often did not last beyond 5 days263, 264, 266. 
Furthermore, the capsid proteins of adenoviral vectors have been found to be toxic to host 
cells and may raise host immune response against infected cells in humans. Therefore, the 
safety of adenoviral vectors has been questioned294. Similarly, measles viruses have also 
been reported to have inefficient transduction within tumors, when investigations of possible 
synergistic application of MV-NIS and radioiodine failed to produce synergistic therapeutic 
effects276. The VSV encoding hNIS also showed promise. However, VACV‘s safety profile is 
unsurpassed, and its high replication capacity and efficient cell to cell spread may enable it 
to overcome many of the limitations with other oncolytic viral vectors. 
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It has been previously discussed86 that VACV gene transcription occurs in a temporal 
manner, with early genes transcribed within the core of the virus particle soon after infection, 
whereas intermediate and late genes transcribe in the cytoplasm of infected cells after viral 
DNA replication295. Early, intermediate, and late mRNA synthesis was detectable within 20, 
100, and 140 minutes of infection, respectively. The strength of VACV promoters, early (PE), 
synthetic early/late (PE/L), and synthetic late (PL) also varies. PE is the weakest among 
these three but is stronger than native early promoters, whereas PE/L has been found to be 
comparable to or slightly stronger than PL. We initially attempted to generate recombinant 
VACVs expressing the hNIS protein under the control of all three promoters (PE, PE/L and 
PL) in order to evaluate the effect of the levels and temporal manner of the hNIS protein 
expression on virus replication, therapy, and imaging. The use of PE/L or PL at the HA locus 
failed to generate any recombinants, as overexpression and/or constitutive expression of 
hNIS seemed to be toxic to the virus. We were able to generate, however, a recombinant 
virus strain that expressed the hNIS protein under the control of PE, GLV-1h153. 
 
GLV-1h153 was effective at infecting, replicating within, and killing PANC-1 cells in cell 
culture and eradicating tumor xenografts as efficiently as parental virus GLV-1h68. This 
indicated that insertion of the hNIS protein did not negatively affect virus replication in animal 
models which was already the case in cell culture, or the cytolytic activity in cell culture and 
virotherapeutic efficacy in tumor xenografts. Since the genes exchanged under the HA locus 
were both under the control of the early promoter PE, these results are not surprising. 
Furthermore, similar effects were seen between the IT and IV groups treated with GLV-
1h153 or GLV-1h68, indicating the inherent affinity of both genetically modified vaccinia 
viruses to tumors. Administration of GLV-1h153 did not have any significant effects on mean 
net body weights of the animals 34 days after treatment, with the IT group even gaining 
weight as compared to untreated control. Furthermore, viral distribution revealed persistence 
of viral infection of tumors even 5 weeks after viral administration at ~109 viral particles per 
gram tissue, with most of the virus cleared from all other organs and trace residual amounts 
found in the lung and kidney.  
 
Microarray analysis revealed an almost 2000-fold change increase in hNIS mRNA and an 
almost 5000-fold change increase by 24 hours after PANC-1 infection with GLV-1h153 at a 
multiplicity of infection of 5.0. Western blot studies showed hNIS protein expression as a 
band between 75 and 100 kDa in PANC-1 cells infected with GLV-1h153, with higher 
concentrations of the protein at higher MOIs. This band also appears in normal human 
thyroid lysates which should contain intrinsic hNIS protein, at a slightly lower molecular 
weight, which is likely explained by differences in glycosylation within cells168. Differences in 
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the expected weight of 97 kDa was seen by other groups, with most also obtaining a band 
between 75 – 100kDa 172, 261, 296, 297. The hNIS protein was successfully transported and 
inserted into the cell membrane, as demonstrated by fluorescence microscopy.  
 
In cell culture, GLV-1h153-mediated expression of the hNIS protein in infected PANC-1 cells 
resulted in specific uptake of the radiotracer 131I in a time and dose-dependent manner, 
indicating that the hNIS protein was functional, The uptake levels were lower in the GLV-
1h153–infected cells compared with the NIS-expressing rat thyroid cell line PCCL3, 
however, in viral-treated cultures, it is likely that not all cells are simultaneously infected with 
virus and express the reporter gene during the early phase of viral infection. During the late, 
prelytic phase of viral infection (48 hours and beyond), the hNIS transporter could be 
impaired due to loss of cell membrane integrity, and following cell lysis, the accumulated 131I 
radiotracer would be lost. Thus, there seems to be a relatively narrow window, ~24 to 48 
hours after viral infection of PANC-1 cells, during which the hNIS reporter is maximally 
functional in cell culture at an MOI of 1.0. These results reflect the dynamic state between 
viral infection, replication, and lysis of tumor cells, and were also seen with the hNET-
expressing virus GLV-1h9986, 159. 
 
In mice, PANC-1 tumors infected with GLV-1h153 were readily detectable by PET, with no 
enhancement above background of either GLV-1h68- or PBS-treated tumors. Mice were 
treated intratumorally with GLV-1h153, non-hNIS expressing parent virus GLV-1h68, and 
PBS, and imaged 48 hours after with carrier free 124I. The quantitative 124I-PET showed that 
the three GLV-1h153-infected PANC-1 tumors were readily detectable with an average 
uptake of 3.82 ± 0.46 %ID/gm 1 hour after radiotracer administration, and no enhancement 
above background of either GLV-1h68- or PBS-treated tumors. Presence of virus in tumors 
was also readily visualized via GFP and bioluminescence imaging. It should be noted that 
the whole tumor is only partially infected with virus and tumor cells are at different stages of 
virus infection at any given time (shown by immunohistochemistry).  
 
The timing of PET imaging after 124I administration was also shown to be important, as 
radioactivity levels (% ID/gm) in GLV-1h153-infected tumors was highest during the first 1-
hour period after tracer administration. This difference is likely the effect of a degree of 
radioefflux from cells, however, the tumor uptake to background ratio actually increased in 
tumors with time, suggesting adequate retention of radioiodine even 8 hours after radiotracer 
injection. This was also seen with other hNIS-encoding viruses264, 270, 271. An exception was 
the adenovirus Ad5/3-24-hNIS, which retained its maximal uptake value 13 hours post 
injection265. Enhanced radiouptake in GLV-1h153-injected tumors compared to other organs, 
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as well as GLV-1h68- and PBS-injected tumors was confirmed in these mice via tissue 
radiouptake assay at 8 hours post radiotracer administration, and correlated well with 
quantative PET. 
 
After establishing that GLV-1h153 enhances radiouptake in tumors in animal models, is 
detected by PET, and induces radiouptake retention, the potential of GLV-1h153 for serial 
imaging and monitoring of both IT and systemic viral therapy was assessed. PET imaging 
readily detected virus replication in tumors as late as 5 weeks post injection. This is in 
contrast to some studies with other oncolytic viruses such as measles and adenoviruses, 
which had signals lasting only around 5 days post virus injection263, 267, 275. Other studies, on 
the other hand, reported the ability of hNIS signal to be detected as far as 30 days post virus 
treatment268, 273. Further, hNIS-mediated radiouptake with GLV-1h153 seemed to peak at 2 
weeks, and gradually decline by week 3 and 5 in both the IT and IV injected groups. This is 
interesting, as although the signal timing pattern in the IV group was similar to other what 
others have found, such as with VSV (51)-NIS and MV-NIS273, 278, the IT group had a much 
more prolonged uptake enhancement. This may be due to the fast replication and spread of 
vaccinia, and could also be due to more rapid cell lysis caused by intratumoral injection of 
the other viruses, which would compromise cell membrane integrity and thus hNIS 
functionality. It should be noted that it is difficult to compare exact values found with other 
oncolytic viruses, as dose effects may differ and are unlikely to be directly comparable. 
Decrease in signal enhancement with GLV-1h153 was despite persistent strong GFP 
expression by 5 weeks posttreatment. GLV-1h153-mediated radiouptake was confirmed via 
GFP, bioluminescence, and CT-PET imaging 1 and 2 weeks post viral injection in both the 
IV and IT groups. All reporter genes were detectable, and fusion of PET and CT images 
correlated enhanced signals anatomically to the location of the tumor, stomach, bladder, and 
thyroid. 
 
When comparing PET signal intensity with tumor growth patterns in mice over 5 weeks, 
enhanced radiosignal appears to correlate with the initial tumor growth, retardation, and 
eventual regression phases. The PET signal remained strong during the first 2 weeks 
postinjection of virus, which reflected initial tumor growth. However, when tumor growth 
began entering a retardation phase, PET signal began to decrease and almost disappear by 
week 5, when tumors have entered the regression phase. Correlation of hNIS-mediated 
uptake and signal patterns was not explored in any other paper investigating oncolytic 
viruses encoding hNIS. It is known that some delay occurs before an actual difference in 
tumor size is noted even after cell death and or necrosis has occurred post viral treatment. 
The only exception was one ITly-treated mouse (M3), where signal persisted up to 5 weeks 
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post GLV-1h153 injection, with an initial decrease in signal suggesting initial cellular death, 
and re-increase in signal, suggesting further tumor cellular proliferation within the tumor. 
Interestingly, the tumor took longer to regress, and maintained a signal up to 5 weeks post 
virus injection. These data suggest that the hNIS reporter gene is able to give insight into the 
biological activity of tumor cells, and whether cell death or necrosis is occurring. Non-viability 
of cells and loss of cell membrane integrity is likely to affect functionality of the hNIS protein 
as shown in cell culture radiouptake experiments, while the GFP reporter protein simply 
suggests viral activity, and once produced seems to persist despite non-viability of tumor 
cells. A similar pattern was observed in the cell culture 131I uptake studies, showing 
decreasing radiotracer uptake at later time points after GLV-1h153 infection also likely due to 
cell lysis and loss of cell membrane integrity. 
 
Histology of serially imaged tumors confirmed wide areas of necrosis and inflammatory 
infiltrate. Necrotic areas were more homogenous in the IVly-treated group, whereas „islands― 
of necrosis surrounded by inflammatory infiltrate was seen in the IT group, reflecting virus 
route of administration. Interestingly, no viable cells were detected histologically in all mice 
tumors except M3 which retained viable tumor proliferation activity. This may again explain 
lack of PET signal in the other imaged mice at 5 weeks post virus injection, and persistence 
of signal in M3. However, it is known from previous viral biodistribution assays that virus can 
persist at even 5 weeks post injection. This may be explained by the fact that virus particles 
can persist in the tumor microenvironment despite non-viability of actual tumor cells, but like 
the GFP signal, persistence of virus does not give insight into the biological activity occurring 
in the tumor cells in response to viral therapy. Further, when higher doses of virus are used, 
124I-mediated PET signals declined more rapidly than with lower doses, suggesting that cell 
death occurs more rapidly with higher doses of virus, especially in the IT groups. This again 
correlated with more rapid tumor retardation and regression. This suggested that virally-
mediated tumor cell death and/or necrosis, and thus hNIS functionality, is dose dependent, 
which was also seen in our in cell culture radiouptake assay. 
 
To determine what conditions are therefore needed for adequate GLV-1h153-mediated 
radiouptake and retention in tumors, autoradiography was performed utilizing 99mTcO4-
mediated Gamma scintigraphy and autoradiography. Areas that lacked GFP, and thus virus, 
and areas noted to be necrotic on H&E staining with lack of blood flow did not support 
uptake. Necrosis could have been virally-mediated or intrinsic due to tumor enlargement. 
However, this further may explain the loss of signal noted with serial monitoring of infected 
tumors, as necrotic areas occurring secondary to viral treatment lacked blood flow and likely 
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functional cell membranes, and thus are unlikely to facilitate hNIS-mediated uptake in 
tumors. No GFP and no uptake were noted in uninfected control tumors despite adequate 
blood flow. 
 
Time-activity concentration data over 72 hours post radiotracer injection generated from 
imaged mice revealed that 124I uptake was maximal at 1 hour post radiotracer injection at an 
average of 8.39 ± 1.23 %ID/gm for the IV group and 10.81 ± 1.10 for the IT group1 week 
post virus injection. Uptake declined over 72 hours in a classic exponential manner, but 
could still be visualized at 24 and even 48 hours after radiotracer injection. Interestingly, 
image and time activity data were similar in week 2, with a slight increased maximal 1 hour 
uptake of 10.14 ± 1.43 %ID/gm for the IV group and decreased maximal uptake of 8.05 ± 
0.01 for the IT group. The decreased uptake in the IT group by week 2 may be due to more 
rapid cell death occurring in the tumors. Uptakes seem to be similar to those mediated by all 
MV-NIS papers and some adenoviruses, but were also much lower than some reported278, 
especially when diet was supplemented with thyroxine and low iodine intake265. This 
highlights the potential of maximizing radioiodine uptake by blocking intrinsic hNIS uptake in 
the stomach and thyroid. 
 
Absorbed doses from image-derived time-activity concentration data of GLV-1h153-infected 
PANC-1 tumors were then calculated assuming 131I treatment. The average absorbed doses 
were 387.02 ± 104.60 rad/mci at week 1 and 352.88 ± 95.45 at week 2 for the IT group. The 
absorbed dose at week 1 post virus injection appears higher in the IV group despite a lower 
maximal radiouptake, signifying longer retention time in the tumor. An estimated 2000 rad 
dose is required for a therapeutic effect to be seen in tumors. Therefore, in order to achieve 
a rad dose of 2000 in the IV-treated group 1 week post injection, around 4-5 mci of 131I was 
estimated to be required. These results are similar to those with MV-NIS in the treatment of 
prostate cancer, with a calculated absorbed dose of 420 and 540rads/mci if injected IT or 
IV273. However, absorbed doses of over 1000 has been calculated with MV-NIS276 and 
VSV278. This could be due to thyroxine supplementation in MV-NIS, but this was not the case 
with VSV. Other factors could include greater viral replication at injected doses, or stronger 
promoter expression of hNIS by these viruses. 
 
Combination therapy of GLV-1h153 and 131I revealed a modest additive effect over GLV-
1h153 alone. While GLV-1h68, and GLV-1h68 with 131I mediated similar therapy effects, the 
GLV-1h153 with 131I group seemed to have more rapid and greater tumor regression. This 
effect, however, was not statistically significant. This is in contrast to several other papers 
showing the potential of enhanced treatment efficacy by combining 131I treatment with hNIS 
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encoding OVs in several different tumor models265, 266, 270, 273, 276, 278. This could be due to 
several factors, including the study not being sufficiently powered, possible lack of 
radiosensitivity of PANC-1 to radioiodine, lack of complete tumor transduction by virus, and 
large tumor volume. A  likely explanation, however, is that lower doses of virus are needed 
to show an additive or synergistic effect, as the virus appears to work very well on its own at 
the selected dose of 2 x 106 PFU. Further work is required to assess the optimum doses of 
virus to be combined with radiotherapy in order to obtain an additive or synergistic effect. 
 
As with any translational therapy, concerns over immune responses remain. Since hNIS is a 
human derived gene, it is unlikely to be immunogenic138. However, application of GLV-
1h153-mediated hNIS transfer raises concerns over the possibility of autoimmunity in 
patients. Several papers have already shown that hNIS is not a major candidate for 
autoimmune disease in patients with patients with Graves' disease and Hashimoto's 
thyroiditis298, 299. Moreover, the clinical trial assessing adenoviral-mediated hNIS transfer in 
humans did not report any serious adverse effects due to autoimmunity in patients treated 
for prostate cancer269. Further studies and caution are needed to assess the potential of 
autoimmunity with hNIS transfer in humans. 
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7.0 CONCLUSIONS 
 
The two most important factors that eventually determine the clinical safety and efficacy of 
any cancer therapeutic are tumor selectivity and anti-tumor potency. Vaccinia virus strains 
are a promising oncolytic virotherapy candidate capable of producing potent antitumor 
effects via cell lysis as well as tumor rejection by stimulating antitumoral immunity. So far, 
clinical trials with oncolytic vaccinia virus constructs indicate that oncolytic vaccinia viruses 
are generally safe and well tolerated in patients with advanced tumors, with certain degrees 
of antitumoral activity demonstrated. However, efforts are still needed to further improve 
safety and efficacy. With many oncolytic viral constructs currently being tested in varied 
phases of clinical trials, intense efforts are now being dedicated to improve efficacy, ability to 
non-invasively monitor therapy, and combine virotherapy with existing treatments for human 
malignancies.  
 
The GLV-1h153 vaccinia construct is a promising candidate for future clinical studies 
combining deep tissue imaging and oncolytic virotherapy. This novel new oncolytic VACV 
engineered to carry the human sodium iodide symporter gene (hNIS) can successfully 
replicate within pancreatic cancer cells as efficiently as its parental virus GLV-1h68, and 
expresses the hNIS reporter gene, which readily facilitated 131I radiouptake in cells. The 
cytotoxicity and safety, as well as tumor-specific imaging, has also been shown following 
treatment of pancreatic tumor xenografts with GLV-1h153. GLV-1h153-treated pancreatic 
tumors were readily imaged with the clinically approved radiopharmaceutical 124I and PET, 
as well as 99mTcO4–mediated gamma scintigraphy. Furthermore, radioiodine dose 
accumulation and retention time in infected tumors reached potentially therapeutic levels, 
and combination of GLV-1h153 and 131I seems promising for more rapid and potent tumor 
regression.  
 
Thus, the ability of GLV-1h153 to infect and image pancreatic cancer, a uniformly fatal 
disease resistant to conventional therapy, justifies further studies as well as the initiation of 
clinical trials. Further, this imaging system could be directly translated to human studies, and 
clinical trials of oncolytic viral therapy would benefit from this noninvasive monitoring 
modality. These findings also warrant further investigation into possible synergistic or 
additive effects of radioiodine combined with this novel new treatment and imaging modality. 
Further investigation is required into the effects of viral dose, tumor size, and metastatic 
disease on imaging capability and potential for targeted radiotherapy with this novel virus.  
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